A comparative study of hormone receptors in spontaneously developed, steroid hormone-induced and carcinogen-induced mammary tumors in female noble rats. by Cheung, Shu Yan. & Chinese University of Hong Kong Graduate School. Division of Anatomy.
A Comparative Study of Hormone Receptors in Spontaneously 
Developed, Steroid Hormone-Induced and Carcinogen-Induced 
Mammary Tumors in Female Noble Rats 
Cheung Shu Yan 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
In 
Anatomy 
• T h e Chinese University of Hong Kong 
August 2001 
The Chinese University of Hong Kong holds the copyright of this thesis Any 
person(s) intending to use a part or whole of the materials in the thesis in a 
proposed publication must seek copyright release from the Dean of the 
Graduate School. 
U L 
‘ f 统 系 银 書 囷 
i 2 l i 1 
一 U 
ilVERSlTY J 園 1 
VtjKl-IBRARY SYSTEl^^ 
Abstract 
Breast cancer is the most prevalent endocrine-related malignancy in women. Several 
animal models are currently available for the study on this cancer. However, a proper 
evaluation on the hormone receptor status on these animal models is still unavailable. 
In the present study, mammary tumors were induced in the adult female Noble (Nb) 
rats by a prolonged combined treatment of estrogen and androgen or by a single dosage of a 
carcinogen, 7,12-dimethylbenz(a)anthracene (DMBA). Spontaneously developed mammary 
tumors were also developed in high incidence rate in the aged female Nb rats. The incidence 
rates, lengths of latency period and histopathology of the mammary tumors developed in 
these three different rat models were compared. In order to investigate the involvement of 
different hormones in the mammary gland carcinogenesis, the expression patterns of estrogen 
receptor (ERa & ERp)，progesterone receptor (PR), androgen receptor (AR) and prolactin 
receptor (PRLR) in these spontaneously developed, hormone-induced and carcinogen-
induced breast tumors were also characterized and compared by immimohistochemistry and 
western blotting. 
The results of immunohistochemistry showed that mammary glands in the normal 
female Nb expressed ERa, ERp, PR, AR and PRLR. Moderate to strong immunoreactivities 
of ERa, ERP, PR, AR and PRLR were also detected in the spontaneously developed and the 
hormone-induced mammary tumors. However, the carcinogen-induced carcinomas exhibited 
a different hormone receptor patterns. Moderate to strong immunoreactivities of ERa, PR, 
PRLR and AR were detected in the mammary tumors. These carcinogen-induced tumors 
expressed a negative to weak ERP immunoreactivity. 
The expressions of the hormone receptors in the mammary tumors of these three 
different models were further investigated by western blotting. It was observed that an 
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expression of the native 67kDa ER protein was detected in the normal mammary glands as 
well as the spontaneously developed, hormone-induced and carcinogen-induced mammary 
tumors. On the other hand, the DMBA-induced neoplasms exhibited a weaker expression of 
this native 67kDa ERa protein. Besides, some of the DMBA-induced tumor samples also 
exhibited a weak expression of the putative 50kDa ERa isoforms. Moreover, the putative 50 
and 54 kDa ERa isoforms were also detected in the spontaneously developed mammary 
tumors. On the other hand, there were expressions of PR isoform, PR-C, in the normal 
mammary glands, spontaneously developed, carcinogen-induced and T+Ei-induced -
mammary tumors. However, in the T+DES induced carcinomas, protein expression of PR-C 
was not detected. It was also observed that mammary glands and all classes of mammary 
tumors induced in female Noble rats express PR-A2 isoforms. Elevated expressions of PR-B 
and PR-Al isoforms were also detected in the spontaneously developed carcinoma. 
Furthermore, an elevated expression of AR isoform, AR-B, was detected in all classes of 
mammary tumors as compared with the normal gland. Expressions of AR-A isoform were 
also detected in the spontaneously developed mammary tumors. Finally, western blot analysis 
for PRLR has detected expressions of the long PRLR isoform in both normal and neoplastic 
mammary samples. 
These observations demonstrate the notion that the process of mammary gland 
carcinogenesis in the DMBA-induced model may be different from that of the spontaneously 
developed and hormone-induced models in the female Noble rats. As mutations of different 
oncogenes and tumor suppressor genes are involved during the mammary gland 
carcinogenesis in these three different animal models, the conversion of the varied genetic 
information into a defined phenotype may lead to a discrepancy in the hormone receptor 
status between the carcinogen-induced mammary tumors and the spontaneously developed as 
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Chapter 1. Introduction 
1.1 Epidemiology of Breast Cancer 
1.1.1 Epidemiology of Breast Cancer in Females 
Breast cancer is the most prevalent malignancy among women, with about 1 
million new cases in the world every year (McPherson et al, 2000). This disease 
accounts for 18 % of all female cancers in the world (Table 1.1). Obviously, breast 
cancer has become a serious worldwide health problem among women. The 
-emot ional , social and healthcare costs related to this cancer are enormous. Therefore, 
breast cancer is such a matter that worthy of our full concerns. 
Although breast cancer shows an overall high incidence in the world, its 
incidence rate varies markedly among countries. The incidence of female breast 
cancer is highest in the United States and Northern Europe, intermediate in the 
Southern and Eastern Europe as well as the South America, but lowest in Asia 
(Parkin et al, 1992). Figure 1.1 shows the international variation in the breast cancer 
incidence among women from 1988 to 1993. 
In the United States, where the highest incidence rate is reported, 
approximately 180,000 women are diagnosed with breast cancer annually (Kelsey 
and Horn-Ross, 1993). This incidence rate predicts that 1 in 8 American women will 
develop breast cancer during her lifetime and approximately 30 % of these women 
will die of this disease (Ries et al, 1998). Currently, breast cancer is the second 
leading cause of cancer deaths among American women after lung cancer and is the 
leading cause of death in the age group between 50 and 55 (Parker et al., 1997). 
Although its number is already .high, adding to the concern is the fact that breast 
. c a n c e r has been rising steadily in all age groups since 1930 (White et al, 1990; 
Parker et al, 1997). 
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Apart from the United States, a nearly doubled sharp increase in the breast 
cancer incidence is also reported recently in the 'traditionally low-risk Asian 
countries such as Japan, Singapore and the urban areas of China since 1950s (Jin et 
al, 1993; Seow et al, 1996;Nagata et al, 1997). 
Although this worldwide rise in breast cancer incidence may be partially 
attributable to the increased use of screening mammography and the aging of the 
population (Chu et al, 1996)，it is undeniable that the increasing number reflects a 
real trend, suggesting that environment or lifestyle changes may be effecting an 
increase in the cancer incidence (Brinton and Schairer et al, 1993; Malone et al, 
1993; Garfinkel et al., 1994). 
Although the incidence of breast cancer shows a global rise, its mortality 
levels off or presents a slight decline in most Western countries since 1990. 
Generally speaking, countries which show a recent downturn in death rate are those 
with the highest incidence and mortality, such as the United Kingdom, Netherlands, 
Sweden and the United States. The countries demonstrating increasing death rates 
tend to be those with the lowest mortality. For instance, Poland and Spain, which 
have the lowest breast cancer mortality among European countries, show a rising 
death rate (Beral et al” 1995; Hermon et al, 1996). 
1.1.2 Incidence and Morality of Female Breast Cancer in Hong Kong 
According to a recent study conducted by the Hong Kong Cancer Registry, 
our society has the highest breast cancer incidence in the Asia, with 1,500 women 
diagnosed annually. Among the local population, it is estimated that one out of every 
forty women will develop breast cancer during her lifetime. 
Over the past 20 years, the incidence of female breasts cancer has been 
• increasing obviously, especially in the age group between 40 and 49 (Figure 1.2 & 
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1.3). The causes for this dramatic rise are uncertain but are believed to be attributable 
to the increasing westernized dietary habits and lifestyle among the population since 
the Second World War. On the other hand, the local death rate due to breast cancer 
has also increased three-fold in the last 20 years. In 1998，it is found that 380 women 
died of this disease, as compared with only 111 sufferers in 1961. Due to this 
dramatic increase rate, breast cancer has overtaken lung cancer as the leading cancer 
among the local females since 1994 (Figure 1.2). 
1.1.3 Epidemiology of Breast Cancer in Males 
In contrast to its prevalence among the women, breast cancer only rarely 
occurs among males in all parts of the world. In the United States, it was reported 
that only approximately 1,600 new cases of male breast cancer were diagnosed and 
400 deaths occurred as a result of this cancer in 1998. Epidemiological statistics 
further showed that male breast cancer only accounts for approximately 1 % of all 
breast cancers and less than 1 % of all annual cancer deaths in the America males 
(Landis et al” 1998). In other populations, the incidence rate of male breast cancer is 
only on the order of 1 case per 100,000 men annually or even less. The highest 
incidence rate of breast cancer is found in Brazil, where an incidence rate of 3.4 
cases per 100,000 males is recorded. In other Asia countries like Singapore and 
Japan，an even lower incidence rate of 0.1 cases per 100,000 is found (Muir et al, 
1987). 
Previous studies suggest that some cases of male breast cancer may be caused 
by pathological conditions that result in relative estrogen excess or lack of androgen 
(Thomas, 1993). The strongest risk factor for developing male breast cancer is the 
Klinefelter's syndrome. It is a rare condition that results from the inheritance of an 
• additional X chromosome (Hultborn et al, 1997). Men with this condition have 
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atrophic testes, gynecomastia, high levels of gonadrotropins and low plasma levels 
of testosterone. This results in high estrogen-testosterone ratid. Men usually need to 
expose to this aberrant hormonal milieu for decades before breast cancer arises. The 
risk of male breast cancer in these individuals is up to 50 times higher than for men 
with a normal genotype (Thomas, 1993). 
As male breast cancer only represents rare cases, in the following sections, 
emphasis will only be put on the female breast cancers. 
1.2 Risk Factors for Female Breast Cancer 
Breast cancer is a complex and multi-staged disease which involves an 
intense interaction between the inherited and the environmental factors. Some of the 
known and established risk factors for breast cancer are categorized in Table 1.2 and 
discussed as follows: 一 
1.2.1 Genetic Risk Factors 
Family history is the most significant known risk factor for the incidence of 
breast cancer. Epidemiological studies show that among all the female breast cancer 
patients，there are about 15 to 20 % of the sufferers have a family history (Slattery 
and Kerber，1993). If early-onset and bilateral breast cancer is found in a woman's 
first-degree relative, which includes the individual's mother, sisters or daughters, she 
will have a high risk to develop the disease (McPherson et al, 2000). 
The susceptibility for breast cancer is generally inherited as an autosomal 
dominance with limited penetrance. It can be transmitted through either gender, with 
some family members possessing the abnormal gene without developing the cancer 
themselves (McPherson, et al, 2000). Two major breast cancer susceptibility genes, 
BRCAl and BRCA2, have been identified and they approximately account for 15 to 
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20 % of familial breast cancer (Slattery and Kerber, 1993). Other heritable breast 
cancer factors are underway to be identified. . . 
The first breast cancer susceptibility gene BRCAl was isolated in 1994 (Miki 
e/ aL, 1994). This breast cancer gene is located on the long amis of chromosome 17. 
The biological ftinction of the BRCAl is still unclear and controversial. However, 
there are accumulated evidences showing that BRCAl plays roles in the gene 
transcription, control of cell cycle as well as the DNA repair pathways (Martin and 
Weber，2000). BRCAl is a large gene. Germline mutation of BRCAl can occur 
nearly in the entire sequence, thereby enhancing the occurrence of a variety of 
imitations within this gene. In general, female with BRCAl mutation have a 60-80 % 
lifetime risk for developing breast cancer and a 20-40 % risk for ovarian cancer 
(Struewing et al, 1996). Breast caners with BRCAl mutations demonstrate a 
number of distinct clinical features including onset in earlier age as compared with 
the sporadic cases，a higher frequency of bilateral breast cancer, and occasionally the 
presence of associated tumors, specifically ovarian cancer and possibly colon and 
prostate cancer (Nelson et al, 1993). 
The second breast cancer susceptibility gene BRCA2 was identified in late 
1995 and is localized to the long arms of chromosome 13, (Wooster et al, 1995). 
S-imilar to that of BRCAl, the function of BRCA2 is believed to be related to the 
DNA damage response pathways (Martin and Weber, 2000). BRCA2 is one of the 
largest genes isolated so far and is approximately twice as large as BRCAl. 
Although the mutations of BRCA2 are not well studied as that ofBRCAl, there are 
more than 250 known mutations spreading throughout the gene have been found. 
The BRCA2-mutation sufferers have cancer risk profile similar, but not identical, to 
to OfBRCAl mutation victims. Lifetime risk for breast cancer in the BRCA2_ 
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mutation victims is about 85 % whereas it is in the range of 10 to 20 % for the 
ovarian cancer risk which is higher than that associated with the BRCAl mutations 
(Ford et al, 1998). Contrary to the male BRCAl mutation carriers, men with 
BRCA2 mutations are associated with a 6 % lifetime breast cancer risk, representing 
a 100-fold increase over the general population. BRCA2 mutations are also linked to 
an increasing incidence in the colon, prostate, pancreatic, gallbladder, bile duct, and 
stomach cancers as well as the malignant melanoma (Cancer Research Campaign 
Genetic Epidemiology Unit, 1999). 
1.2.2 Hormonal Risk Factors 
Breast cancer is an endocrine-related cancer. The breast carcinogensis and 
the subsequent tumor progression are directly associated with exposure to hormones, 
particularly the estrogen, which may contribute to the mammary gland 
carcinogenesis by increasing the cell division and rate of cell proliferation, thereby 
enhancing the accumulation of random genetic errors (Preston-Martin et al, 1991). It 
is generally believed that prolonged or increased exposure to either endogenous or 
exogenous estrogens will result in an increased breast cancer risk (Persson, 2000; 
Clemons and Goss，2001). Therefore, the hormone-related factors including early 
menarche，late menopause and nulliparity, that will increase the number of menstrual 
cycles and subsequently enhance the endogenous estrogen exposure, are able to 
increase the breast cancer risk. Similarly, factors that are related to the supplement of 
exogenous estrogen will also increase one's likelihood for breast cancer 
development. Examples are administration of oral contraceptives and estrogen 
replacement therapy for the menopausal women. On the other hand, reduction in the 
total number of ovulatory cycles, which can be achieved by moderate level of 
exercise and longer lactation period, are found to be protective against breast cancer 
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incidence (Martin and Weber, 2000). These endogenous and exogenous breast 
cancer risk factors are discussed individually in the following.‘ 
1.2.2.1 Endogenous Hormonal Risk Factors 
Epidemiological studies have showed that women who start menstruation 
early in life and have a late menopause will suffer from an increased risk of 
developing breast cancer. This clearly demonstrates that the breast cancer is related 
to the ovarian steroid hormones. Solid evidences are illustrated by the fact that 
women who start menarche at age 12 or earlier with rapid establishment of regular 
cycles have an almost fourfold risk on breast cancer, as compared with women who 
menstruate at age 13 or older with longer duration of irregular cycles (Henderson et 
al, 1985). On the other hand, females who have natural menopause after age 55 are 
twice more likely to develop breast cancer than individuals who experience the 
menopause before the age of 45 (McPherson and Dixon, 2000). 
The geographic variations in the breast cancer prevalence may also be 
explained by the differences in the menarcheal and menopausal ages. In Asia, where 
a lower breast cancer incidence is observed, earlier menacheal and later menopausal 
ages are reported, as compared with the corresponding data in the United States, 
which shows the largest breast cancer numbers. 
Pregnancy is the other endogenous hormonal factor related to the breast 
cancer risk. Both nulliparity and late first birth are reported to be able to raise one's 
lifetime breast cancer susceptibility (Kelsey and Gammon, 1993). The highest risk is 
found in females who give their first birth after the age of 35. These individuals also 
show a higher breast cancer frequency than the nulliparous women. In contrast, early 
N 
full term pregnancy is protective against this cancer. Women with early second birth 
can further reduce the breast cancer risk (McPherson and Dixon, 2000). The 
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mechanism by which fiill-term pregnancy alters subsequent breast cancer risk is 
unknown, although it is generally believed that it may due to the priming effect 
brought by the terminal differentiation of breast epithelium during the pregnancy 
(Martin and Weber, 2000). 
Finally, body weight is also a suspected risk factor. It is found that obesity 
can result in twofold increase in the breast cancer risk in postmenopausal women 
(McPherson and Dixon, 2000). This observation in postmenopausal women may be 
attributed to the fact that the majority of endogenous estrogen comes from the 
conversion of androstenedione to estrone in the adipose tissue, and thus, obesity will 
result in the long-term increase in estrogen exposure. 
1.2.2.2 Exogenous Hormonal Risk Factors 
Due to the close association between the endogenous hormone secretions and 
the breast cancer risks, the potential influences of exogenous estrogen have evoked 
widespread attentions. 
Since the introduction of oral contraceptives for birth control in 1960s, there 
have been many studies to analyze its possible influence on the breast cancer risk. 
However, the results are inconsistent and such controversial results may be due to 
the temporal changes in hormone dosages as well as the drug delivery methods 
(Fraser, 2000). Overall, it is now believed that oral contraceptive will only cast a 
small risk on the users. Nevertheless, females who are currently using the oral 
contraceptives and are in extended use will have higher breast cancer risk than the 
general population (Martin and Weber, 2000). 
On the other hand, hormone replacement therapy, which is mainly adopted 
by the postmenopausal women for the relief of menopausaul symptoms, reduction in 
cardiovascular disease and delay in osteoporotic complications, has also been under 
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extensive studies (Torgerson, 2000). Short-term uses of estrogen replacement are 
shown to be safe but the risk on breast cancer development will increase annually 
after continuous usage for 5 years. Although the use of hormone replacement therapy 
is beneficial to postmenopausal women, it is still a possible risk for the women, 
especially for the long-term users and individuals with family history on breast 
cancer or personal history on dysplastic breast disease. Regular check-up for the 
breast and endometrial cancer is recommended for those women with hormone 
replacement therapy (Purdie, 2000). 
The synthetic estrogen, diethylstilbestrol (DES)，was widely prescribed to the 
pregnant females in order to minimize pregnancy complications and prevent 
abortions between 1943 and 1971. However, subsequent studies have indicated that 
administration of DES during the period of mammary gland proliferation, such as the 
pregnancy, can significantly increase one's breast cancer risk. This drug has also 
been found to cause other serious physical and psychological damage to the pregnant 
users and to their offspring. This drug is now no longer prescribed (Saunders, 1988). 
1.2.3 Other Risk Factors 
Some examples of the risk factors for breast cancer have been reported. 
These include personal history such as increasing age, previous history of 
hyperplastic disease or cancer history, radiation exposure as well as lifestyle such as 
high-fat diet, excess alcohol intake and smoking (Martin and Weber, 2000; 
McPherson and Dixon, 2000). Among these factors, age is the most significant 
environmental risk factor. It is estimated that the susceptibility on breast cancer will 
double every decade until menopause in women, after which a sharp reduction in the 
� 
increase rate is observed. This positive relation between age and breast cancer 
incidence is attributable to the lifetime accumulation of carcinogenic mutations 
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whereas the dramatic decline in breast cancer risk after menopause is explained by 
the reduction in endogenous estrogen production (McPherson and Dixon, 2000). 
1.3 Oncogenetic Basis of Female Breast Cancer 
Current views on the oncogenetic basis of female breast cancer suggest that 
the malignant transformation of the normal breast epithelium into an invasive 
carcinoma is a multistep process, in which a number of genetic alternations have 
occurred within various critical genes, that are directly or indirectly responsible for 
regulating certain important cellular processes, such as cell proliferation, 
differentiation, chromosomal replication and apoptosis (Lakhani, 1999). These 
genetic alternations can be induced by either the internal or external causes. The 
internal causes, which all arise from the body itself, include those risk factors such as 
- early menarche, late menopause, nulliparity, aging, obesity and the inheritance of 
mutated BRCAl or BRCA2 gene. On the other hand, the external causes are 
environmental factors such as the administration of oral contraceptives, hormone 
replacement therapy, radiation exposure, high-fat diet, excess alcohol intake and 
smoking. Overall, no single factor can fully explain the incidence of breast cancer. 
Instead, breast cancer is a complex disease, of which the development involves 
interplay of a number of etiologic agents, and they arise either internally or 
externally (Weinstein, 1988). These internal or external etiologic agents can either 
activate or inactive the affected genes. For a cancer to develop, oncogenes should be 
activated whereas tumor suppressor gene should be inactivated (Weinberg, 1989). 
Oncogenes are a class of genes that can either stimulate cell division or 
prevent cell death, thereby possessing the ability to cause tumor growth and 
development if these genes are activated. In humans, oncogenes are rarely activated 
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by viruses, such as the mouse mammary tumor virus (MMTV) in murine. Instead, 
activation of oncogene is commonly triggered by one'of three major mechanisms, 
mainly by amplification of genes, occasionally by alterations of amino acids and 
chromosomal translocation. In the amplification mechanism, multiple copies of 
genes are reproduced in a single chromosome. By increasing the gene dosage, the 
corresponding protein products are over-expressed, thereby facilitating distorted 
cellular development. Examples of the breast caner related oncogenes activated by 
this amplification mechanism include epidermal growth factor receptor (EGFR), 
erbB-2/HER-2/neu, c-myc and cyclin Di, all of which can stimulate cellular 
divisions (Devilee et al, 1994). 
Tumor suppressor genes are a class of genes that can inhibit tumor growth 
when in normal functioning. For a tumor to develop, both of the functional tumor 
suppressor alleles on a single chromosome must be inactivated by mutations, which 
occur mainly sporadically rather than by inheritance. In breast cancer, the most 
commonly mutated tumor suppressor gene is p53, which is a checkpoint regulator in 
the cell cycle and it monitors the fidelity of mitosis. In the absence of p53, 
chromosomes segregate aberrantly and cells soon become polyploid. Inherited 
mutation of p53 is seldom a sole cause of breast cancer. Instead, p53 principally 
alters by sporadic somatic mutation. It is found that nearly half of all invasive breast 
tumors will carry a mutated p53 (Devilee et al , 1994). In comparison, mutation of 
the tumor suppressors BRCAl and BRCA2, which are involved less than 10 % of all 
breast cancer case, are mainly inherited and thus, seldom found in the sporadic breast 
cancer (Rajan et al, 1996). On the other hand, some tumor suppressors such as Rb 
and pi6，which are parts of the EGF responsive pathway and associated with 
stimulating cell division, are rarely mutated in breast cancer. 
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Currently, our understanding on the genetic basis of breast cancer is still 
incomplete, extensive studies are now underway to ‘ identify more breast cancer 
related oncogenes and tumor suppressors genes. 
1.4 Hormonal Basis of Female Breast Cancer 
The mammary gland is a target organ by a number of ovarian and pituitary 
hormones. The normal development of the breast as well as the pathological 
progression of the breast tumors are under strict control and influence by an 
extensive interplay between hormones and growth factors, which are secreted by the 
hypothalamus, pituitary, adrenal gland, thyroid gland and particularly the ovary 
(Russo and Russo, 1998). Of all the hormones involved, estrogen, progesterone and 
prolactin are considered in great significance, but the role of androgen is still 
ambiguous. The following sections give a detailed review on these hormones and 
their role in mammary gland carcinogenesis. 
1.4.1 Mechanisms of Hormone Action 
1.4.1.1 Estrogen and Progesterone 
The ovarian steroid hormones, estrogen and progesterone, are well-
established tropic factors that promote proliferation and differentiation of the breast 
epithelial cells. The expression and presence of both the estrogen and progesterone 
receptors in the breast epithelium gives strong support that the action of these two 
steroids in the mammary gland is mainly mediated by binding to their nuclear 
receptors (Figure 1.3). The activated hormone-receptor complex then migrates to the 
nucleus, complements to the target hormone-responsive genes and finally modulates 
the transcription of genes. (Russo et al, 1999; Hansen and Bissell, 2000). 
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Estrogen receptor (ER) exists in two isoforms, ERa and ERp, each being 
encoded by separate genes (Girdler and Brotherick, 2000). In the normal mammary 
glands and some breast tumors, there is a co-expression of ERa and ERp. However, 
it is still uncertain whether these two isoforms have the same or different 
physiological roles in the normal and neoplastic mammary tissues (Osborne, 1998; 
Nass and Dividson, 1999). 
On the other hand, progesterone receptor (PR) also exists in two isoforms, 
namely PR-A and PR-B. Unlike the ER subtypes, PR isoforms are transcribed from 
two distinct transcription start sites within the same gene (Clemm, 2000; Hansen and 
Bissell, 2000). These two receptor isoforms show differences in the transcriptional 
activation properties and have distinct expression ratios in various target organs. For 
instance, PR-A isoform is predominantly expressed in the rodent mammary gland, in 
a ratio of 3:1 in comparison with the PR-B. The appropriate cellular responsiveness 
to progesterone is believed to be dependent on the regulated hormonal activity as 
well as the accurate PR isoform expression ratio. Imbalanced PR expression may 
cause inappropriate progesterone signaling which will result in aberrant mammary 
development (Shyamala et al, 1999). Additional pieces of evidence shows that 
progesterone signaling may also be affected by the presence of a third PR, PR-C, a 
protein missing the first 594 amino acids at the common N-terminus of PR-A and 
PR-B. At present, the role of PR-C is still not well defined (Hansen and Bissell, 
2000). 
Finally, other ER and PR variants and mutants are also present and may 
contribute to the hormonal sensitivity and development of the breast tumors. 
N 
However, their roles in mammary gland carcinogenesis are still not defined yet. 
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More studies are required to define their roles (Osborne, 1998; Hansen and Bissell, 
2000). • 
In the mammary gland, estrogen and progesterone are mutually regulating 
each other's activities. In female breast, the expression and synthesis of PR is under 
positive estrogenic regulation. On the other hand, progesterone antagonizes estrogen 
action by decreasing the replenishment of ER and promoting the synthesis of 17P-
hydroxysteroid dehydrogenase which results in the accelerated metabolism of 
estrogen to the inactive estrone form (Shyamala et al, 1999). 
1.4.1.2 Prolactin 
Prolactin also mediates its function through receptor binding (Figure 1.4). 
After binding to its specific cell membrane-spanning receptor, the peptide hormone 
activates subsequent signaling pathway, leading to the transcription of target genes, 
which may induce mammary proliferation, differentiation as well as the lactogenesis 
(Hennighausen et al, 1997). 
Prolactin receptor (PRLR) principally exists in two isoforms, the long and the 
short PRLR, which are generated by alternative splicing from a single gene and only 
differs in the length of their cytoplasmic domains. Long PRLR is dominantly 
expressed in the breast whereas its short form counterpart is mainly found in the liver 
(Shirota et al, 1990). The third intermediate form, the Nb2 form, is a deletion 
mutation in the cytoplasmic domain of the long PRLR. Both the long and short 
PRLR present in the normal and malignant mammary cells. In some breast tumors, 
expression of the Nb2 from is also detected (Hennighausen et al, 1997). 
1.4.2 Hormonal Regulation of Normal Breast Development 
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The normal breast development is divided into several stages. At birth, the 
mammary gland only consists of few primary ducts embedded the mammary fat pad 
with seldom branching. Between birth and puberty, the growth of the mammary 
tissues is mainly hormone-independent and there is primarily an increase in amount 
of stromal tissue. During this prepubertal period, estrogens in the developing females 
will interact with the primary epithelial-stromal unit to promote mammary ductal 
development and enhance its penetration into the fatty tissue. In contrast, androgen 
inside the developing male interacts with the epithelial-stromal unit to induce 
destruction of the under-developed mammary epithelium (Nass and Davidson, 
1999). 
Following the priming effects brought by estrogens, the mammary gland of 
the prepubertal females remains quiescent until the establishment of the full 
menstrual cycles during puberty. Estrogen, which is secreted at maximal level by the 
ovaries during ovulation, brings about an extensive mammary ductal proliferation. 
On the other hand, the ovulatory progesterone is responsible for the lobuloalveolar 
development by enhancing mammary cell differentiation. Prolactin is mainly 
synthesized by the anterior pituitary and to a lesser extent produced locally by the 
breast (Binait et al, 2000). Prolactin is responsible for the maturation of the primary 
mammary ductal system. It promotes lobuloalveolar branching from the terminal end 
buds. The terminal end buds will regress after the completion of its differentiation 
into alveolar buds and lobules (Horseman, 1999). 
Estrogen plus progesterone, prolactin and other hormonal factors, when 
secreted in an adequate balance, give a complete and proper development of the 
� 
mammary gland. The full mammary maturation is characterized by the regression of 
terminal end buds with the presence of highly branched lobular ducts (Horseman, 
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1999). After sexual maturity, the development of mammary glands stops 
fundamentally, although the epithelial tissue shews alternating rounds of 
proliferation and apoptosis in responsive to the cyclic hormonal stimuli by the 
ovarian steroids during menstrual cycle. The greatest increase in mitotic index of the 
mammary gland occurs during the luteal phase. This suggests that progesterone is 
responsible to this mammary periodic change (Nass and Davidson, 1999). 
During pregnancy, prolactin, progesterone, estrogen and other endocrine 
factors like placental lactogens stimulate further lobuloalveolar differentiations. 
After this physiological lobuloalveolar development has been completed, the 
mammary gland becomes competent to carry out lactation. The delivery of prolactin 
and other factors such as growth hormone (Feldman et ai, 1993)，in the context of 
falling progesterone secretions, stimulates gene expressions of various milk proteins 
and subsequently leads to the lactogenesis (Horseman, 1999). 
After lactation, there is a decline in hormone secretions and it initiates the 
involution of mammary gland. During the weaning period, the basement membrane 
of glandular alveoli breaks down and extensive cellular apoptosis occurs. After 
involution has been completed, the mammary gland only composes of a highly 
branched ductal system with some remaining alveoli (Nass and Davidson, 1999) 
1.4.3 Hormonal Regulation of Breast Carcinogenesis and Its Subsequent 
Progression 
N 
Breast cancer is a multi-stepped and hormone-related disease. The initial 
malignant transformation and the subsequent cancer progressing processes, such as 
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invasion, migration, angiogenesis and evasion of immune system, are largely 
dependent on hormonal regulation, which may act in the endocrine, paracrine or 
autocrine manners (Nass and Davidson, 1999). The ovarian steroids, estrogen and 
progesterone, as well as the pituitary prolactin are the active participants in these 
processes. On the other hand, androgen may also play a role in the breast cancer 
development. The roles of different hormones on the mammary carcinogenesis are 
reviewed as follows. 
1.4.3.1 Androgen 
Although there is widespread co-expression of androgen receptor (AR) with 
ER and PR in human breast tumors, the role of androgen and its receptor in female 
breast cancer is still controversial as androgen is described having both the cancer 
growth stimulatory and inhibitory effects in human breast cancer cell lines. The 
mechanisms by which androgens exert these conflicting effects in cancer cell lines 
and also in breast cancer tissues are still unknown. To determine the role of the AR-
mediated pathways in regulating breast tumor growth, further studies are warranted 
(Birrell et al, 1998; Bry&sacute, 2000). 
Recently, additional pieces of evidence are available from the animal studies 
and the experimental results indicate that androgen might play a role in the 
mammary carcinogenesis. In both the male and female Noble (Nb) rats, it has been 
found that a combined androgen and estrogen prolonged treatment was able to 
induce high incidence of mammary tumors within relatively short time. The 
supplement of androgen was found to be able to shorten the tumor latency period, as 
compared with the corresponding data on the estrogen-induced mammary tumors in 
Nb rats (Liao et al, 1998; Xie et al, 1999; 1999b). 
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Overall, the action of androgen on breast cancer is speculated to be multi-
discipline. On one hand, androgen promotes the proliferation of breast cancer cells 
directly via the androgen receptor-mediated mechanism or by its stimulation on the 
synthesis of other growth factors. On the other hand, the action of androgen may be 
indirect. Firstly, androgen can be converted into estrogen by the enzyme aromatase, 
(Bernstein and Ross, 1993). Estrogen, derived from the systemic conversion in 
peripheral tissues or from the local conversion in the breast tumors, participates in 
the maintenance and growth of the breast tumors in the carriers, especially in the 
postmenopausal females (Chen, 1998). Alternatively, androgen acts indirectly by 
increasing the circulating amount of free estradiol, via either reducing the secretions 
of hepatic estradiol-bound sex hormone binding globulin (SHBG) by the liver or 
decreasing the fraction of the SHBG, thereby providing substantial amount of 
estrogen for tumor growth (Lonning et al, 1995). 
1.4.3.2 Estrogen 
The most well-documented risk factors of breast cancer, such as early 
menarche, late menopause and nulliparity, are associated with the most significant 
physiological changes in the estrogen secretion during a female's lifetime. This 
� strongly suggests that estrogen plays a very important role in the development of the 
human breast cancer. 
Clinical studies have found that about two thirds of the primary breast tumors 
are ERa-positive. In comparison with the ERa negative tumors, neoplastic tissue 
expressing ERa are generally more well-differentiated, grow more slowly and are 
‘ associated with longer disease-free survival (Osborne, 1998). Expression of ERa in 
breast cancer also shows important significance for prognosis, as generally ER-
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positive tumors are more responsive to endocrine therapy with antiestrogens such as 
tamoxifen. Although multiple lines of evidence also show that ERp is also expressed 
in both the normal and malignant breast cells, the contribution of this ERp 
expression to the development of normal and tumorigenic breast cells is still 
completely undefined at present (Osborne, 1998; Girdler and Brotherick, 2000). 
In the functional studies, estrogen was found to be able to stimulate cell cycle 
progression in the ERa expressing cancer cells, which results in the proliferation of 
breast tumors. In addition to its role as- a mitogen, estrogen also acts as a survival 
factor for the ER-positive tumor cells as estrogen ablation is commonly followed by 
induction of apoptosis. It is believed that estrogen maintains the tumor survival by 
modulating the expression of an antiapoptotic protein, Bcl-2. This belief is based on 
the observation that the increases in Bcl-2 expression in breast cancer cells can be 
significantly inhibited by the administration of anti-estrogens (Nass and Davidson, 
1999). 
Other studies have demonstrated that when the ERa positive breast tumors 
continue to develop, estrogen may finally lose its influence and the tumors become 
no more responsive to either estrogen or tamoxifen. Several possible mechanisms are 
proposed to explain this progression of hormone-independence. These include the 
ligand-independent ER activation, the expression of variant or mutant ER forms as 
well as the altered expression of the downstream estrogen targets (Ferguson and 
Davidson, 1997). Furthermore, it is observed that when the ERa positive primary 
breast tumors have invaded to a secondary site, up to 30 % to 40 % of this metastases 
. will become ERa negative (Kuukasjarvi et al, 1997). As estrogen is responsible for 
promoting growth and survival of ERa positive cells, loss of ER expression may be 
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an important step in the progression of breast tumors into a more aggressive form, 
and this represents that the cancer cells have acquired the ability to bypass the ERa 
pathways for growth and survival. In these ERa negative tumors, inhibition of ER 
gene transcription is a likely mechanism responsible for the loss of ERa expression. 
This inhibition may be achieved by the methylation of cytosine-rich areas, termed 
CpG islands, in the 5' regulatory region of the ERa gene (Lapidus et al, 1996). 
1.4.3.3 Progesterone 
“ Besides estrogen, progesterone can also enhance the proliferation of breast 
cancer cells. Studies using agents targeting the activity of progesterone receptor have 
shown that these agents can alter subsequent tumor growth. Administration of 
antiprogestins and pharmacological dosage of progesterone can generally result in 
the inhibition of cancer growth. A mechanism has been proposed recently to account 
for this mitogenic action by progesterone. This hypothesis is based on the 
observation that during the luteal phase of menstrual cycles, the elevated secretion of 
progestine is generally accompanied with a rise in the growth hormone production 
by the hyperplastic mammary epithelium as well as an elevated growth hormone 
level in the serum. This elevated local expression of mammary growth hormone can 
be blocked significantly by antiprogestins. Therefore, it is proposed that this 
progesterone-induced systemic and local growth hormone synthesis, instead of 
progesterone itself, are responsible for the cyclic breast cell growth during the luteal 
phrase and the proliferation of the breast cancer cells (Mol et al, 1996). 
Currently, it is still uncertain whether progesterone is a survival factors for 
the breast cancer cells or not. However, in the normal mammary gland, it is reported 
that progesterone can inhibit apoptosis during involution (Feng et al, 1995). Apart 
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from the ERa, the PR expression is also an important prognostic indicator for breast 
cancer. PR is found co-expressed in about 50 % of all' ERa positive breast tumors. 
This reflects that ERa is a key transcriptional factor for the expression of PR (Read 
et al, 1988). The absence of PR expression in ERa positive tumors may imply 
nonfunctional or aberrantly functioning ERa and the neoplastic cells are no longer 
influenced by the administration of anti-estrogens. This theory is consistent with the 
clinical findings that double-positive tumors usually are responsive and amenable to 
endocrine therapy, in the frequency of about 75 %, whereas in the ERa-positive/PR-
negative tumors, the frequency drops dramatically and only less than one third 
initially responds, and nearly all ERa-negative/PR-negative tumors rarely respond to 
tamoxifen (Nass and Davidson, 1999). It is widely believed that the absence of PR 
expression is also associated with the methylation in the regulatory region of the PR 
gene (Lapidus et al, 1996). — 
In most breast tumors, it is found that PR-A and PR-B were expressed in 
similar amounts. The remaining proportion of breast tumors usually expresses a very 
low level of PR-B. However, the clinical significance of this expression pattern of 
PR-A and PR-B has not been addressed yet (Graham et al, 1996). 
1.4.3.4 Prolactin 
Prolactin is well-known for its active involvement in the growth and 
differentiation of the normal mammary gland as well as its role in the initiation and 
V 
maintenance of lactation (Vonderhaar, 1999). The role of prolactin in mammary 
cancer has been clearly demonstrated in rodents. Prolactin is found directly 
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contributing to the etiology of both spontaneously developed and carcinogen-
induced murine mammary carcinoma (Welsch and Nagasawa, 1977). Prolactin also 
acts synergistically with ovarian steroids to promote the growth of human breast 
cancer xenografts in mice (Leung and Shiu, 1981). In rats, there is a direct 
association between the serum prolactin level and the susceptibility of different rat 
strains to the chemical carcinogen induction of mammary tumors (Boyns et al., 
1973). Tumors induced in rat by carcinogens, nitrosomethylurea (NMU) or 7,12-
Dimethyl-benz[a]-anthracene (DMBA) are dependent on prolactin for sustained 
growth (Mershon et al, 1995). Prolactin is also a mitogen for human breast cancer 
cells in culture, and anti-prolactin reagents can inhibit the growth of these cells 
(Ginsberg amd Vonderhaar, 1995). 
In contrast to this clear demonstration in the rodent models, the role of 
prolactin in human breast tumorigenesis is poorly defined because there is a lack of 
correlation between circulating prolactin levels and the incidence of breast tumors, 
and treatments that suppress pituitary prolactin release have not been shown to 
improve clinical outcome. 
Nevertheless, a breakthrough is achieved recently. It is now known that 
prolactin can also be produced in many extrapituitary locations, including both the 
-normal and the malignant breast epithelial cells (Vonderhaar, 1999). On the other . 
hand, it is also found that prolactin receptors, both long and short form, are widely 
expressed in the normal glands and the mammary cancers. These findings lead to the 
hypothesis that locally produced prolactin in the breast tumors act as an autocrine or 
paracrine factor to support neoplastic growth, which is independent of the circulating 
. prolactin levels (Reynolds et al., 1997; Vonderhaar, 1999). Besides, there are also 
evidences showing that proalctin may also function synergically with estrogen and 
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progesterone to regulate the growth of normal and malignant breast tissues. In one 
study in a large panel of human breast cancer cell lines and primary tumors using 
quantitative Northern blot analysis, there shows a positive correlation between the 
expression levels of PRLR and that of ER and PR. In these breast cancer cell lines, 
treatment with progestins and estrogen was found to be able to increase PRLR 
expression while addition of exogenous prolactin resulted in elevated PR levels 
(Ormandy et al, 1997). 
Furthermore, growth hormone and prolactin are closely related pituitary 
hormones. Human growth hormone is found to be able to bind to and activate both 
I 
growth hormone receptor (GHR) and PRLR. It is proposed that there is a cross-
regulation between growth hormone and prolactin in the mammary carcinogenesis 
(Wennbo and Tomell, 2000). 
1.5 Animal Models for Breast Cancer 
Breast cancer is a very complex disease. Until now, our understanding on this 
disease is still incomplete and we still lack effective strategies for the prevention and 
cure on the breast cancer. In order to have a complete picture on the pathogenesis of 
this cancer, experimental animal models that highly mimic the human breast cancer 
are certainly needed. Breast cancer is comprised of a heterogeneous group of 
diseases, characterized by different sets of genetic mutations, histopathological types 
and metastatic potentials. Even in the same primary tumour mass, the neoplastic 
mammary cells would show heterogeneous phenotypic characteristics. Therefore, it 
. is unlikely that any single animal models will be able to mimic all the aspects in 
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human breast cancer. However, this will not reduce the values of each animal model 
to study specific aspect of the human breast cancer. 
Although animal models for the breast cancer are available in various 
mammalian species, such as monkeys (Zhou, et al, 2000)，dogs and cats (Vail and 
MacEwen, 2000)，the majority of experimental models are limited to the rodent 
species. It is because many rodent strains could develop spontaneous mammary 
tumors, and respond to a variety of carcinogenic agents such as hormones, 
chemicals, radiations, viral or transgenic factors, with development of either 
hormone-dependent or -independent mammary tumors, all of which show striking 
resemblance on the histopathology to the human breast cancer. The most common 
rodent models for the breast cancer include spontaneously developed, carcinogen-
induced, virus-induced, hormone-induced, radiation-induced rodent models as well 
as the transgenic mouse model and the human tumor xenografts, with each model 
possessing its own advantages and limitations. 
1.5.1 Mouse Models 
The mouse models for human breast cancer include a variety of transgenic 
mice, gene deletion mice and naturally mutated mice. The analysis of transgenic 
mice, which express regulatory genes in a deregulated fashion, has provided insight 
into the function of these genes in the development of normal breast and breast 
cancer. On the other hand, the establishment of gene deletion or knockout model has 
identified genes which play critical roles in mammary gland development and 
carcinogenesis. Finally, the ^natural mouse mutants that exhibit altered mammary 
. gland development have also provided useful information on the oncogene basis of 
the breast cancer. 
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In contrary to the rats, there are number of mouse strains which are 
susceptible to virus infections and develop mammary tumors in these mice. The 
mouse mammary tumor virus (MMTV) is the best example of these virus-induced 
mice models. MMTV is able to infect the neonatal female mice through the foster 
rat's milk. The infected female mice will develop preneoplastic hyperplastic alveolar 
nodules as early as in 4 weeks of age. The vims induced murine mammary tumors 
usually exhibit strong hormone dependence on estrogen, progesterone (Osborne et 
al, 1990) and prolactin (Welsch and Gribler, 1973). 
Although the murine models have contributed ‘ much to the present 
understanding of insertional mutagenesis and oncogene activation in the mammary 
tumorigenesis (Callahan, 1996)，there are only a few corresponding human 
homologues are found mutated in human breast cancer. It has been criticized that 
these murine models may not necessarily represent the exact genetic events 
occurring in human breast cancer. 
1.5.2 Rat Models 
In the present study, expression patterns of hormone receptors in three Noble 
rat models are investigated. They include the chemical-induced model, hormone-
induced model and the spontaneously developed models. In the following sections, a 
detailed review on these three models will be given. 
1.5.2.1 Carcinogen Induced Rat Models 
The carcinogen-induced rat model represents the most popular experimental 
• systems used for studying human breast cancer. In this model, mammary tumors are 
usually induced in the Sprague-Dawley (SD) rat by 7,12-Dimethylbenz[a]anthracene 
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(DMBA) or in the SD rat or Fischer 344 rat by iV-Methyl-TV-Nitrosourea (NMU). The 
usage of DMBA was first described by Huggin in 1961 (Huggins & Yang, 1962) 
whereas NMU has been used increasingly in the last two decades (Thompson & 
Meeker, 1983). In both models, a single dosage of chemical carcinogen is usually 
administrated to the animals, either by gavage as for the DMBA or by intravenous or 
intraperitoneal injection as for the NMU. The tumor latency period generally ranges 
between 8 to 21 weeks, and with final tumor incidences near to 100 % (Russo et al, 
1990). The advantages of this animal model, such as ease in tumor induction, short 
tumor latency period and high tumor incidence, make this rat model popular for the 
study of human breast cancer. 
It was also reported that the susceptibility of the rat mammary gland to either 
the DMBA or NMU-induced carcinogenesis is strongly dependent on the age of rats. 
A maximal tumor incidence will only be obtained when the chemical is administered 
to the virgin animals at the age of sexual maturity, that is between the age of 7 and'8-
weeks-old. The reason for this observation is still uncertain, but may be related to the 
active proliferation of mammary gland during this maturity period. 
With unknown genetic reasons, different rat strains show a different and 
deviated .susceptibility to DMBA- or NMU-induced mammary tumorigenesis. 
Among the most commonly used rat strains, SD and Wistar-Furth are the most 
susceptible; Fischer 344 and ACI rats show intermediate susceptibility, whereas 
Copenhagen rats essentially completely resistant to the carcinogen treatment (Russo 
et al, 1999). It was reported that Noble rats are also susceptible to the chemical 
� 
treatment, with a high induction yield of adenocarcinoma, occasionally 
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fibroadenoma but also associated with the incidence of leukima (Noble and Cutts, 
1959; Carroll and Noble, 1987). ‘ ‘ 
Although there is the close resemblance of the tumor behaviors induced by 
the carcinogens, DMBA and NMU, some differences between the properties of these 
two chemicals are noted. Unlike NMU, DMBA requires metabolic activation for its 
carcinogenicity (Singletary, 1990). Several tissues are capable of activating DMBA. 
However, the mammary and hepatic activation are believed to be the most important 
factor for the DMBA-induced tumorigenesis. In contrast, NMU does not require 
metabolic activation, and it is frequently associated with ras gene mutations (Bos, 
1989). Mutations of ras gene seldom occur in the DMBA-induced breast tumors. 
These discrepancies between DMBA and NMU suggest that the cellular signaling in 
the mammary carcinogenesis induced by DMBA and NMU are different. 
The carcinogen models possess several characteristics that closely mimic to 
its human counterparts. Previous studies show that rats having completed a full-term 
pregnancy and lactation before carcinogen treatments exhibit a reduced incidence of 
the induced tumor (Russo et al, 1990). In human, epidemiological studies have 
indicated that full-term pregnancy and lactation is protective against the breast 
cancer risk (Martin and Weber, 2000). On the other hand, many of the rat mammary . 
tumors arisen from carcinogen induction are well-differentiated adenocarcinoma, of 
which the histopathology is highly similar to a significant proportion of human 
breast tumors (Russo et al, 1990). Furthermore, the chemically induced tumors are 
generally responsive to estrogen and prolactin (Mershon et al, 1995), with 
� 
subsequent development into hormone-independence. Although the role of prolactin 
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is still not evident in human breast cancer (Vonderhaar, 1999)，the loss of prolactin 
responsiveness is also frequently reported in the rat mammary tumors. 
Human breast is an endocrine-dependent organ. In daily life, it has little 
chance to come in contact with or only has low exposure levels to chemical 
carcinogens. Therefore, it is not surprising that in some aspects, the behaviors of the 
chemically induced rat mammary tumors are different from their human 
counterparts. For instance, in the carcinogen-induced rat mammary tumors, there is a 
high incidence of mutations on certain oncogenes, such as the ras activation in the 
NMU-induced carcinogensis, and they are very rare in human breast cancers (Bos, 
1989; Zhang et al., 1990). 
1.5.2.2 Hormone Induced Rat Models 
As stated above, the physiological development of normal breast and the 
malignant progression of mammary cancer are tightly regulated by hormones, 
particularly the estrogen. This provides the basis for the hormone-induced rat model. 
As compared with the chemical induced model, in which the malignant 
transformation of mammary gland is initiated by chemical carcinogen, hormone-
induced rat models are more closely mimic to the pathological conditions of the 
human breast carcinogenesis, as only naturally occurring hormones are used to 
induce the incidence of mammary cancers. 
In many female rat strains, continuous exposure to estrogen alone can lead to 
the development of mammary tumors (Noble and Cutts, 1959). AGI rat, which is an 
inbred line derived from a cross between the August and Copenhagen strains, 
appears unique among all the rat strains as it is highly susceptible to estrogen-
induced mammary tumorigenesis but rarely develops mammary cancers 
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spontaneously or in response to the chemical carcinogen or ionizing radiation 
(Harvell et al., 2000). The ability of female ACI rats to develop high incidence of 
mammary carcinoma in response to the synthetic estrogen diethylstilbestrol (DES) 
was first noted by Dr. Dunning WF as early as in 1947 (Dunning et al, 1949; Noble 
and Cutts, 1959). Recently, it was reported that ACI rats are also sensitive to the 
naturally occurring estrogen, 17p-estradiol, and results in a high mammary 
carcinoma incidence within relatively short time (Shull et al, 1997). Interestingly, 
with uncertain reasons, its genetically closely related strain, Copenhagen rat (COP) 
is found to be resistant to the mammary tumor induction, no matter by the estrogen, 
chemical carcinogen or the ionizing radiation (Korkola and Archer, 1999). 
More than four decades ago, Dr. Noble RL and his colleagues had conducted 
a series of detailed and influential studies on the induction of malignant mammary 
tumors in both male and female Noble rats employing subcutaneously implanted 
estrone pellets as the only inductive agent (Noble and Cutts 1959; Cutts, 1964; Cutts 
and Noble, 1964; Noble et al, 1975). According to their pioneering studies, Noble 
rats was chosen because this rat strain showed a consistently high susceptibility to 
the estrone treament and is well tolerated to the hormone pellets. Although SD rats 
also showed estrone susceptibility, they tolerated the treatment poorly and mortality 
- , 
was high. On the other hand, Fischer and Wistar rats were found to be tolerated to 
the hormone well but they only showed low mammary tumor incidence. Similarly, 
Lewis rat strain showed comparable tumor incidence as that of the Fischer and 
Wistar rats but was intolerant of the drug and frequent death was resulted. 
X 
In his pioneering study, Dr. Noble reported that the natural incidence of 
mammary tumors in Noble rat strains was very low. However, after estrogenization, 
29 
the incidence of mammary tumors became more common in both sexes, particularly 
in the aged animals. The average latency period for the estrogen-induced tumor was 
9 to 11 months, with incidence ranged from 60 to 80 %. However, increasing the 
estrone dosage was unable to alter both the tumor latency period and the incidence 
rate. Although benign fibroadenomas were occasionally collected, the majority of the 
induced mammary tumors were of epithelial origin, being various types of malignant 
carcinoma. Unlike the chemically induced mammary tumors, estrogen-induced 
carinomas sometimes showed metastasis to other secondary tissue sites including 
lymph nodes, liver and lung. The histopathology of the tumor cells is highly 
heterogenous, in which different histological types are often noted within the 
identical microscopic view of the same tumor. It was also reported that the induced 
tumors are hormone-dependent, removal of the estrogen markedly inhibits the 
growth of the neoplastic cells and is followed by tumor regression, whereas 
reinsertion of estone pellets usually resulted in tumor reappearance. Although 
multiple tumors were frequently found in individual Noble rats, the estrogen-induced 
mammary tumors usually appeared singly in each mammary gland (Noble and Cutts 
1959; Cutts, 1964; Cutts and Noble, 1964; Noble et al, 1975). 
Although there are studies demonstrating that androgen inhibits normal 
breast development and suppresses the growth of natural occurring (Labrie et al, 
1992)，carcinogen-induced (Costlow et al, 1976, Dauvois et al, 1989) and estrogen-
induced mammary tumors (Dauvois et al, 1991; Zhou et al, 2000)，simultaneous 
treatment with both androgen and estrogen in both male and female Noble rats was 
found to be able to induce high incidence (over 50 %) of mammary tumor within 
. relatively short time (6 to 9 months) (Liao et al, 1998; Xie B et al, 1999). The 
Noble rat cancer model has demonstrated that androgen can pose a promoting effect 
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in the mammary carcinogensis, as the addition of androgen treatment was found to 
be able to shorten the tumor latency period significantly. These recent findings have 
greatly improved the values of Noble rat as an animal model for the study of human 
breast cancer. In addition, Noble rat can provide the researchers not only a model for 
the study of male breast cancer but also an appropriate experimental system to study 
the ambiguous role of androgen in mammary carcinogenesis. 
1.5.2.3 Spontaneously Developed Rat Models 
Spontaneous mammary tumors are not uncommon in rats, particularly in the 
aged female populations. The most commonly used rat strains, which are allowed to 
live their normal life span, show a significant high incidence of spontaneous 
mammary tumors (Table 1.3). 
According to the pioneering studies by Dr. Noble RL, spontaneous mammary 
tumors were rare in Noble rats, although the tumors developed more commonly in 
animals over 1 year of age. Dr. Noble reported that in a Noble rat colony of 565 
females and 299 males, the incidence of benign fibroadenoma in female Noble rats 
below 1-year old was about 8 % while that of the carcinoma was 1 %. In those 
females aged over 1 year, the incidence of the fibroadenoma sharply increased to 22 
o/o whereas the carcinoma incidence risen to 3 %. In contrast, the incidence of 
spontaneous mammary tumors in male Noble rat was not evident, only 2 % of the 
animal was found bearing the mammary fibroadenoma (Noble et al, 1975). These 
figures demonstrate clearly that age and sex are the two most important factors 
influencing the incidence of spontaneous mammary tumors. Although exact data 
. may vary from one rat strain to others, spontaneous tumors develop more commonly 
in the aged animals, normally when the rat is over 1-year-old. The figures also 
31 
indicate that female animals are much more susceptible than males to develop 
spontaneous mammary tumors (Table 1.3). The reasons for this observation are 
unclear. It may be attributable to the lifetime accumulations of carcinogenic 
mutations in the aged animals and the high systemic estrogen levels in the female 
animals. Unlike the murine model, no virus is found to be able to induce mammary 
tumors in rat species so far (Noble and Cutts, 1959). 
The Table 1.3 summarizes the incidence of spontaneously developed 
mammary tumors as reported by different laboratories. However, there are variations 
of the tumor incidences reported between different and even in the same laboratories. 
For instance, in the female SD rats, spontaneous mammary tumor incidences of 55 %, 
62 %, 64 % and as high as 85 % have been reported. The tumor incidences in male 
SD rats also range from 19 % to 44 % (Sher, 1972). It is believed that lot of factors 
affect the spontaneous tumor incidence. These includes habitat environment such as 
the dietary content, the bedding, the temporal length of dark/light cycle, background 
radiation and other factors such as the presence of carcinogen or virus, the length of 
study，the age and mortality of the animals, the sample numbers, the germline 
mutations of the rat colony (Noble and Cutts, 1959; Sher, 1972). 
Although there are variations in the incidences reported on the spontaneously 
developed mammary tumors, some rat strains are resistant to the induction of breast 
tumors and they only show a low incidence rate of the spontaneous mammary 
tumors. Generally, breast tumors accounts for 30 to 95 % of all the spontaneous 
tumors found in the female animals, as reported in the female SD, Wistar and August 
rats. However, in Copenhagen rats, which are resistance to mammary tumorigenesis, 
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only a 5.6 % of the spontaneously developed tumors are of mammary origins (Noble 
and Cutts, 1959). • ‘ 
As compared to all the models induced by carcinogens or hormones, the 
whole process of carcinogenesis in the spontaneously developed model is naturally 
occurring and without any exogenous factors. This model is closely mimic to the 
mammary carcinogenesis in human. Apart from its close resemblance to human 
breast cancer, the spontaneous developed model is also an excellent experimental 
system to study the early neoplastic transformation of the mammary gland. In 
contrast to the chemical or hormone-induced models, in which malignant tumors are 
common, the spontaneous developed tumors collected in our colony frequently show 
hyperplastic and dysplastic samples as well as a high proportion of begin adenoma or 
fibroadenoma, although occasionally highly malignant carcinomas were also 
collected. It is believed that the spontaneously developed model could provide a 
useful model to elucidate a complete picture on the malignant transformation events 
occurring during the mammary gland carcinogenesis from the early hyperplasia to 
the invasive carcinoma. This greatly facilitates our understanding on the human 
breast cancer. 
In spite of the above-mentioned advantages, the incidence rates of the 
spontaneous mammary tumors are low and uncertain. Large numbers of animal 
should be maintained to their normal life span in order to collect significant quantity 
of the spontaneous mammary tumors for analysis and the costs involved are 
prohibitively expensive to most laboratories. Due to this reason, the experimental use 
of the spontaneously developed models is still limited. 
1.6 Aims of Study 
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Noble rat is a valuable animal model for the study of human breast cancer in 
addition to prostate cancer. On one hand, this rat strain is susceptible to the hormonal 
treatment. On the other hand, according to our unpublished experience, Noble rat is 
also sensitive to the carcinogen induction and is able to develop mammary tumors 
spontaneously in a high incidence. Therefore, Noble rat strain can offer the 
researchers a valuable tool to study the similarity and difference between the 
phenotypic behaviors of the mammary tumors induced by various treatments. In the 
present study, the incidence rates, lengths of latency period and histopathology of the 
spontaneously developed, hormone-induced and carcinogen-induced mammary 
tumors of female Noble rats were compared. In order to investigate the involvement 
of different hormones in the mammary gland carcinogenesis, the expression patterns 
of estrogen receptor (ERa & ERp)，progesterone receptor (PR), androgen receptor 
(AR) and prolactin receptor (PRLR) in these spontaneously developed, hormone-
induced and carcinogen-induced breast tumors were also characterized and 
compared by immunohistochemistry and western blotting. The comparison on the 
phenotypic behaviors of the spontaneously developed, hormone-induced and 
carcinogen-induced mammary tumors are believed being able to provide us insights 
on the underlying carcinogenic mechanisms on the mammary glands in these three 
different rat models. . 
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Table 1.1 Worldwide Incidences of Cancers in Women in 1980 
(McPherson et al, 2000) 
Anatomical Sites of Cancer Number of Cases (per 1000s) Percentage of Total 
Breast “ 丽 18 
Cervix 466 15 
Colon and Rectum 286 9 
Stomach 261 8 
Endometrium 149 5 
Lung 147 5 
Ovary 138 4 
Mouth and pharynx 121 4 
Oesophagus 108 4 
Lymphoma ^ 3 
Table 1.2 Risk Factors for Breast Cancer 
(McPherson et al, 2000) 
Risk Factor Relat iveHigh Risk Group  ^  
GENETIC 
Family History ^ Breast cancer in first degree relative when young 
HORMONAL 
Age at menarche 3 Menarche before age 11 
Age at menopause 2 Menopause after age 54 
Age at first fUll pregnancy 3 First child in early 40s 
Taking exogenous hormones: 
Oral contraceptives 1.24 Current use 
Hormone replacement 1.35 Use for ^ 0 years 
therapy 
Diethylstilbestrol 2 Use during pregnancy 
Obesity: 
Premenopausal 0.7 Body mass index >35 
Postmenopausal 2 Body mass index >35 
OTHERS 
Age >10 Elderly 
Geographical location 5 Developed country 
Diet 1.5 High intake of saturated fat 
Radiation exposure 3 Abnormal exposure in young females after age 10 
Alcohol consumption 13 Excessive intake  
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Table 1.3 Incidence Rates of Spontaneous Mammary Tumors in Common Rat 
Strains 
Rat Strains Spontaneous mammary tumors Incidence Rate  
Female Male 
Sprague-Dawley Fibroma 0.3% -
(Chandra er z^/., 1992) Fibroademoma 18.96% 0.75% 
Adenoma 3.54% 0.60% 
Adenocarcinoma 8.8% 0.15% 
Total Incidence 31.3% 2.3% 
Wistar Fibroademoma 25.26% 1.13% 
(Walsh and Poteracki, 1994) Adenoma 4.38% 0.15% 
Adenocarcinoma 13.14% 1.02% 
“ Total Incidence 42.78% 2.3% 
Fischer 344 Fibroademoma 11.1% -
(Chandra and Frith, 1992) Adenoma 1.9% -
Adenocarcinoma 1.6% -
Total Incidence 14.6% 0% 
Noble Fibroadenoma 22% 2% 
(Noble era/., 1975) Carcinoma 3% 0% 
Total Incidence 25% 2% 
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Figure 1.1 International variation in age-adjusted female breast cancer from 1988 to 
1993 (Parkin et al.，1997) 
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Chapter 2. Materials and Methods 
2.1 Origin and Supply of Noble Rats 
The black-hooded Noble rat strain was originated from Dr. JB Collip's 
laboratory at McGill University in 1940s. This rat colony was believed to arise from 
outcross between the Long-Evans rats and the Wistar rats, and the Long-Evans rats 
were from Dr. Philip Smith at Columbia University. Subsequently, Dr. RL Noble of 
the Cancer Research Centre in Vancouver further developed a distinct inbred Noble 
rat strain from this original stock. The rat strain which Dr. RL Noble successfully 
developed was of random littermate breeding and was characterized by black-
hooded, moderately sized, readily breeding and extremely docile, thereby ideal for 
experimental works. In 1970s, the Medical Research Council (Carshalton, England) 
assigned this colony as Noble (Nb) rat after evaluation on its genetic composition 
and degree of inbreeding contributed by Dr. RL Noble. The offspring was then 
randomly bred for later experiments (Noble et al, 1975). 
In the present study, breeders of Nb rats were obtained originally from the 
Charles River Breeding Laboratories in Japan in 1996. The strain is then being 
maintained by the Laboratory Animal Service Centre, the Chinese University of 
Hong Kong. Young adult animals of suitable age were used in the present study. In 
addition, female Sprague-Dawley rats were also used for the induction of mammary 
tumors by A/'-methyl-A^-nitrosourea (NMU). 
2.2 Supply of Materials 
Unless specifically stated, all the chemicals used in the present study were 
obtained from Amersham Pharmacia Biotech. (NJ, USA), Boehringer Mannheim 
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(Mannheim, Germany), Fluka (Buchs, Switzerland), GibroBRL (USA) and Sigma 
Chemical Company (St. Louis, USA). ‘ 
The antibodies used were obtained from Affinity Bioreagents (Colorado, 
USA), Jackson ImmunoResearch Labs (USA), NeoMarkers (California, USA), Santa 
Cruz Biotechnology (California, USA) and Zymed Labs (San Francisco, USA). 
2.3 Induction of Mammary Tumors by Singe Dose of Chemical 
Carcinogens in Female Rats 
2.3.1 Induction by 7,12-Dimethylbenz[a]anthracene in Female Noble Rats 
Female virgin Noble rats at 7 to 8 weeks of age were used. The carcinogen 
7,12-Dimethylbenz[a]anthracene (DMBA; Sigma, USA) was dissolved in com oil at 
a concentration of 10 mg/ml. Single dose of DMBA emulsion was administrated into 
the Noble rat intragastrically at a dosage of 50 mg/kg body weight using a 16G 
curved blunt-ended gavage needle. The control rats were administered with com oil 
only. The treated rats were then housed in cages and fed on normal chows and 
drinking water ad libitum. After treatment for 2 months, the animals were palpated 
regularly for the detection of mammary tumors. The animals were killed when they 
became morbid or when obviously palpable lumps of mammary tumors were 
detected in the mammary gland. The mammary tissues were then collected for 
subsequent studies. 
2.3.2 Induction by iV-Methyl-A^-Nitrosourea in Female Sprague-Dawley rats 
Female Sprague-Dawley rats of 7 to 8-week old were obtained from the 
Laboratory Animal Service Centre, the Chinese University of Hong Kong. Upon 
arrival, the carcinogen A^-Methyl-iV-Nitrosourea (NMU; Sigma, USA) was stored at 
“ 4°C in dark. A 20 mg/ml NMU solution was freshly prepared by dissolving the 
chemical in normal saline (0.85% NaCl) containing 0.05% acetic acid. Only freshly 
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prepared NMU solution, which was used within 30 minutes after preparation, was 
used for the tumor induction. A single dose of NMU solution was then injected 
intraperitoneally at the lower left quadrant of the rat abdomen at a dosage of 50 
mg/kg body weight. Age matched untreated rats were used as controls for the 
experiment. The rats were then fed on normal chows and drinking water ad libitum. 
After NMU administration for over 2 months, the animals were palpated regularly 
for the detection of mammary tumors. Suspected mammary lumps were then excised 
from the animals for further analysis. 
2.4 Induction of Mammary Tumors by Long-Term Treatments 
with Steroid Hormone 
2.4.1 Preparation of Steroid Hormone-filled SilasticCe/Tubings 
Silastic®laboratory tubings of inner diameter of 1.67 mm and outer diameter 
of 3.18 mm (Catalogue Number 508-008; Dow Cowing; Michigan, USA) were cut 
into lengths of either 1 cm or 2 cm. The 2-cm tubings were tightly filled with 
powder of testosterone (T; Sigma, USA) while the 1-cm tubings were packed with 
either 17P-estradiol (E2； Fluka, USA) or diethylstilbestrol (DES; Sigma, USA) using 
an air pump. Both ends of the steroid hormone-filled tubings were then sealed with 
the Silastic®medical adhesive (Silicone type A; Dow Coming). When the sealing . 
adhesive became hardened, tubings were soaked overnight in 70% ethanol in order 
to ensure complete sealing of tubings and removal of hormone powder residues 
adhered to the tubing surface. The tubings were then immersed in 0.5M phosphate 
buffered saline (PBS) for another 2 days. Finally, the tubings were blotted dry with 
Kimwipes tissue, stored at 4°C and were ready for surgical implantation into the 
Noble rats. 
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3.4.2 Surgical Implantation of Silastic(ETubings 
Virgin female Noble rats of 7 to 8 weeks of age'were used. The animals were 
anaesthetized by intraperitoneal injection of 7 % chloral hydrate solution at a dosage 
of 0.5 ml/lOOg body weight. The implantation site was located over the skin between 
the scapulae and the skin was shaven with an electric clipper. The hairless operating 
area was then cleaned with 70 % alcohol. The skin was cut open and a subcutaneous 
pocket was made by blunt dissection beneath the skin in a caudal direction. Blunt 
forceps were used to make the tubing accommodation, in which testosterone-
implants (T) were inserted to the left scapula whereas the estrogen-implants (DES or 
E2) were placed on the right side. After implantation, the tubings were pushed 
subcutaneously into the inguinal region. The incision was sutured and sprayed with a 
permeable wound dressing (Smith & Nephew Medical Limited, England). The 
animals were housed in cages 皿d fed on normal chows and drinking water. After the 
tubing implantation, regular palpation of the animals was made for mammary tumor 
detection. 
2.4.3 Protocols of Hormonal Treatments 
The animals under hormonal treatments were divided into two groups, 
namely combined T+E2 group and combined T+DES group. For combined T+E2 
group, two 2-cm testosterone tubings and one 1-cm 17p-estradiol tubing were 
implanted subcutaneously (Leav et al, 1988). For combined T+DES group, similar 
protocol was applied but diethylstilbestrol tubings instead of 17p-estradiol tubings 
were implanted into the rats. For the control group, age-matched intact virgin female 
Noble rats, without tubing implantation were used. 
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2.5 Collection of Spontaneously Developed Mammary Tumors in 
Noble Rats 
About 3-mouths-old intact adult male or virgin female Noble rats were 
housed in cages with room lighting on 12 hours light/dark cycle. The animals were 
fed on normal chows and drinking water ad libitum. Routine observation was made 
to check for morbidity and mortality. The animals were palpated regularly up to 2 
years and were killed when they became morbid or when obviously palpable lumps 
were detected in the mammary gland. -
2.6 Transplantation of the Spontaneously Developed Mammary 
Tumors into Noble Rats 
Intact aged female or male Noble rats bearing spontaneously developed 
mammary tumors were regarded as donor animals for the tumor transplantation. On 
the other hand, intact Noble rats of the same sex as the donor animals were used as 
host animals receiving the spontaneously developed mammary tumors. The host 
animal was adult rat of about 3 months old. Both the tumor-bearing donors and the 
host Noble rats were anaesthetized by intraperitoneal injection of 7 % chloral hydrate 
solution. The tumor transplantation site was made over the skin between the scapulae 
of the host Noble rats. The operating area was shaved with an electric clipper and 
then cleaned with 70 % alcohol. An incision was made and a small subcutaneous 
pocket was created by using a pair of blunt-ended scissors under the skin in a caudal 
direction. On the other side, the spontaneously developed mammary tumor was then 
quickly dissected from the donating Noble rat and rinsed briefly with saline in a Petri 
dish. It was then immediately transferred to a second dish containing Hank's saline. 
All extraneous tissue adhered to the tumor was removed and only the solid viable 
tumor tissue was selected for transplantation. The selected tissue was transferred 
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quickly to a third Petri dish containing Hank's buffer, in where the tumor was cut 
into small pieces with size of about 5 mm^ in size for subsequent transplantation. A 
fat pad was then extracted from the subcutaneous pocket of the host animals. A 
minute cavity was made in the fat pad. One to two pieces of tumor fragment were 
transferred to the fat pad cavity with a pair of fine forceps. Subsequently, the tumor-
containing fat pad was carefully pushed back into the subcutaneous pocket, in a 
position as far from the skin incision site as possible in order to prevent any loss of 
• e tumor pieces. After transplantation, the incision sites on both the donator and 
host animals were sutured and sprayed with a permeable wound dressing. The 
animals were housed in cages and fed on normal chows and drinking water ad 
libitum. The rats were inspected routinely in order to check the conditions of the 
donating animals and the growth of the transplanted tumor pieces in the host rats 
2.7 Bilateral Ovariectomy of Female Noble Rats Bearing 
Spontaneously Developed Mammary Tumors 
Female Noble rats bearing spontaneously developed mammary tumors were 
ovariectomized bilaterally. The animal was first anesthetized by intraperitoneal 
injection of 7 % chloral hydrate solution. The anaesthetized animal was then laid 
ventrally. A small incision of about 1-2 cm was made on the midline dorsal skin, at a 
position of about halfway between the hump of the back and the base of the tail. 
Scissors were then inserted subcutaneously through the skin incision. Blunt 
dissection was carried out on skin beneath on either side of the incision for a short 
distance, in order to access to the abdominal muscles under the skin. The skin 
incision was retracted with forceps, first to one side and the abdominal muscle wall 
. was cut open in order to get into the abdominal cavity. The ovary was exposed and 
ligated before excision. Similar procedure was done on the other side and the other 
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ovary was excised too. Approach into the abdominal cavity on the either side was 
made by making a small cut of the abdominal muscle wall. The muscle incisions 
were located half to two-thirds of the way down the rat's spinal column. The ovary, 
which was embedded in a variable amount of fats, could be exposed easily from the 
muscle incision. After successfully exposing the ovary, its periovarial! fat was gently 
grasped. The ovary was then carefully pulled out from the animal's abdominal 
cavity. The junction between the Fallopian tubes and the uterine horn was ligated. 
The ovary, with all the accompanying blood vessels and periovarian fat, were 
excised over the fallopian tubes beyond the ligation site. The uterine horn was then 
returned into the animal's abdominal cavity. Subsequently, the muscle incision was 
sutured. The skin incision was then retracted with forceps to another side to remove 
the remaining ovary. Identical procedures for removal of the ovary were followed. 
After bilateral ovariectomy, the skin incision was sutured and sprayed with a 
permeable wound dressing. The animals were housed in cages and were fed on 
normal chows and drinking water. Routine inspection was made in order to check the 
post-surgery recovery of the animals and the growth of the transplanted 
spontaneously developed mammary tumors in the animals. 
2.8 Measurement of Mammary Tumor Growth 
After ovariectomy, the size of the spontaneously developed mammary tumors 
in the animals was determined weekly. Each dimension of the tumor diameter was 
measured three times using an electronic digital caliper. Result was expressed as 
tumor volume, which could be obtained using the following formula (Boven et al., 
1985): 
Mammary Tumor Volume = Vi x length x width x height 
43 
2.9 Whole Mount Preparation of the Hormone-Treated 
Mammary Glands in Noble Rats 
This whole-mount protocol was provided by Dr J Russo, Breast Cancer 
Research Laboratory, Fox Chase Cancer Center, Philadephilia, USA. The hormone-
treated Noble rats were anesthetized with an intraperitoneal injection of 7% choral 
hydrate solution. The animals were placed on its back with the four extremities 
stretched on a surgical board. The skin was opened by a longitudinal midline incision 
extending from the submaxillar to the public regions. The skin was separated from 
the muscle by gently pulling the skin and blunt dissection with scissors. Fixation for 
whole mount preparation was obtained by removing the skin pelt with all the 
mammary glands attached. The skin pelt was stretched and pinned to a corkboard -
and then immersed in 10% neutral buffered formalin for 24 hours. After fixation, the 
mammary glands were identified by locating the corresponding nipple. They were 
then dissected starting the nipple and processed dorolaterally. The mammary fat pad 
was lifted with forceps. It was separated from the subcutaneous tissue by dissection 
with iris scissors or a scalpel. Tissues were defatted by submersion in acetone for 2 
or more days. The acetone was changed when it became cloudy. The containers with 
glands and acetone were placed on a shaker bath. All the defattening procedure was 
preformed under continuous agitation at approximately 80 rpm. The tissues were 
hydrated in decreasing concentrations of ethanol: 100 %，95 % and 70 % for 1 hour, 
each with continuous agitation before processing with the staining in toluidine blue. 
The whole process of staining and washing of the mammary tissues were 
carried out in continuous agitation. The tissues were stained in 0.025% Toluidine 
Blue solution for 2 hours. The tissues were washed in distilled water for 30 minutes. 
. The tissues were then destained in pure methanol and 70 % ethanol for 30 minute 
respectively. The tissues were subsequently washed in distilled water and fixed in 4 
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% ammonium molybdate for 30 minutes. The tissues were washed again in distilled 
water for overnight. The tissues were then dehydrated in 70 %, 95 % and 100 % 
ethanol for 1 hour each. The tissues were transferred to xylene overnight and finally 
mounted to slides. 
2.10 Histological Examination of the Mammary Gland and Tumors 
in Noble Rats 
The Noble rats of different treatment groups were palpated regularly for the 
inspection of mammary tumors. The animals were killed when obviously palpable 
lumps were detected in the mammary gland. The palpable mammary lumps were 
then quickly excised from the anaesthetized animals. Abdominal mammary glands 
were also collected form the normal and lactating untreated Noble rats as a control 
comparison. The excised tissues were fixed by immersion overnight in 4% 
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The fixed tissues were washed 
thoroughly in running water, dehydrated through graded ethanols, cleared in xylene 
and embedded in paraffin. Paraffin sections of 5|im in thickness were cut and stained 
with hematoxylin and eosin (H&E). After dehydration in alcohol and xylene, the 
sections were mounted in Permount® for light microscopic study. The mammary 
tumors were graded histopathologically using the criteria as outlined by Dr. Jose 
Russo and Irma H. Russo, Fox Chase Cancer Centre, USA (Russo & Russo，1978, 
1987; Russo etal, 1977，1979, 1982，1983). 
2.11 Detection of Protein Expression of Hormone Receptors in 
Normal Mammary Glands and Mammary Tumors of Noble Rats 
2.11.1 Antibodies 
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The primary antibodies used for the immimohistochemical and Western blot 
analysis were as follows: a rabbit polyclonal androgen'receptor (AR) antibody C19 
raised against the last 20 amino acids of rat AR C-terminal (Santa Cmz 
Biotechology，California, USA); a rabbit polyclonal estrogen receptor a (ERa) 
antibody MC20 raised against the last 20 amino-acids of rat ERa C-terminals (Santa 
Cruz Biotechology, California, USA); a rabbit polyclonal estrogen receptor p (ERp) 
antibody PA1-310B raised against to the C-terminal amino acid residues 467-485 of 
rat ER beta (Affinity Bioreagaents, Colorado, USA); a rabbit polyclonal 
progesterone receptor (PR) antibody C20 raised against the amino acids 545-564 of 
human PR, the segment differing from the same region of rat PR in two amino acids 
(Santa Cruz Biotechology, California, USA); a mouse monoclonal prolactin receptor 
(PRLR) antibody clone U5 specific to the extracellular portion of the rat liver PRLR 
(Affinity Bioreagaents, Colorado, USA); a mouse monoclonal prolactin receptor 
(PRLR) antibody clone T6 specific to the ligand binding site of the rat liver PRLR 
(Affinity Bioreagaents, Colorado, USA). A mouse monoclonal multi-keratin 
antibody clone C-11 (NeoMarker Carlifomia, USA), which could recognize the rat 
keratins 4，5，6，8，10，13 and 18，were also used for immimohistochemical study in 
order to correlate the hormone receptor expression patterns with the mammary tumor 
histopathology. 
For the immunohistochemistry, avidin-biotin peroxidase complex method 
(ABC method) was used to amplify the immunohistochemical signals on sections. 
The biotinylated secondary antibody used in the present study included goat anti-
rabbit IgG, donkey anti-mouse IgG and donkey anti-goat IgG (Jackson 
Immunoresearch Labs, USA). 
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For Western blotting, an alkaline phosphatase-mediated colorimetric method 
was used to detect the antibody binding sites on the PVDF membrane. The alkaline 
phosphatase conjugated secondary antibodies used in the Western blot analysis 
included goat anti-rabbit IgG, goat anti-mouse IgG and rabbit anti-goat IgG (Zymed 
Labs, USA). 
2.11.2 Immunohistochemistry 
Normal Noble rat mammary glands or tumor tissues were fixed overnight in 
4% paraformaldehyde in O.IM phosphate buffer, pH 7.4. Other organs included 
lactating mammary gland, uterus, liver and prostate were also collected from normal 
Noble rats for fixation and were used as control tissues for immunohistochemistry. 
The fixed tissues were then embedded in paraffin. Paraffin sections of 5 |im in 
thickness were dewaxed in xylene and hydrated in graded ethanols. The hydrated 
sections were treated with 0.5 % hydrogen peroxidase in absolute methanol for 30 一 
minutes in order to remove the endogenous peroxidase activity. The sections were 
then rinsed in phosphate buffered saline (PBS), pH 7.4，for 5 minutes. Antigen 
retrieval was preformed by heating the sections in O.IM Tris-HCl containing 0.5 % 
urea，pH 9.5 for 10 minutes at 95°C. The sections were then remained in the same 
buffer solution for additional 15 minutes at room temperature and washed in PBS for 
2 times, 10 minutes each. The sections were incubated in a blocking solution 
containing 0.1% bovine serum albumin (BSA) and 0.05% Triton X-100 in PBS for 
30 minutes. The sections were incubated with the diluted primary antibody (1:200 in 
the blocking solution) in a moist chamber overnight at 4�C. For control sections, the 
sections were incubated in the blocking solution without the antibodies. After 
overnight incubation, the sections were washed in PBS with 3 changes, 15 minutes 
“ each. After washings, the sections were incubated with the biotinylated secondary 
47 
antibody for 1 hour at room temperature in a humid chamber. After the incubation, 
sections were rinsed with PBS for 15 minutes. The imihunohistochemical signals on 
the sections were detected by the avidin-biotin peroxidase complex (ABC) method 
(Hsu and Raine, 1981). In brief, an ABC complex solution was prepared by mixing 
10 |j.g avidin (EY Laboratories, San Mateo, USA) and 2.5 |ig biotin-conjugated 
horseradish peroxidase (Jackson ImmunoResearch Labs, USA) in 0.05 M PBS. The 
ABC mixture was allowed to stay at room temperature for 30 minutes prior to 
applying to the sections. The sections were then incubated with the ABC complex 
for 1 hour at room temperature in a moist chamber. After incubation, the sections 
were washed in PBS for 3 changes, of 15 minutes each. The peroxidase activity was 
then visualized by a glucose oxidase-diaminobenzidine (DAB)-nickel intensifying 
procedure (Chan and Choi, 1995). In brief, the sections were first pre-incubated in an 
ammonium nickel sulfate-DAB solution (0.4 g ammonium nickel sulfate, 20 mg p-
D-glucose, 4.0 mg ammonium chloride and 5.0 mg DAB in 10 ml 0.1 M acetate 
buffer, pH 6.0) for 10 minutes. Glucose oxidase (0.5 mg per 2.0 ml distilled water; 
Type VII，Sigma) was then added to the DAB solution. The positive reaction sites 
were demonstrated as a dark blue or black color. The reaction was stopped by 
incubating the sections in 0.1 M sodium acetate, pH 6.0，and subsequent washing in 
running tap water. Finally, sections were dehydrated in graded ethanols, cleared in 
xylene, mounted with Pennount®and examined under the light microscope. 
2.11.3 Protein extraction, SDS-PAGE and Western blotting analysis 
Freshly dissected normal mammary glands or mammary tumors were 
immediately frozen in liquid nitrogen. The frozen samples were stored at — 70°C 
until protein extraction. Multiple samples of equal amount of normal mammary 
gland or tumor tissues induced or developed by the same treatment were pooled 
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together from at least three individual animals. The pooled samples were 
homogenized (Polytron PT 2000, Brinkmann) in 10-fold volumes (per gram wet 
weight tissue) of cold lysis buffer in an ice-bath. The lysis buffer contained 20 mM 
PIPES, 0.25 M sucrose, 1 mM EDTA，1 mM EGTA, 10 mM monothioglycerol, 50 
mM sodium fluoride, 0.5 mM sodium orthovanadate, 0.5 mM PMSF, 2 ug/ml 
aprotinin and 5 ^M leupeptin. The homogenates were centrifiiged at 12,000 r.p.m. 
for 20 minutes at 4°C. The supernatant was collected and its protein concentration 
was determined by the bicinchoninic acid protein assay (BCA protein assay, Pierce, 
USA) with bovine serum albumin (BSA) as standard. The quantified protein samples 
were aliquoted in small volume and kept at until electrophoresis (Liao et al, 1998). 
Before gel electrophoresis, the protein samples were first mixed with 0.2 
volume of 2x sample buffer (0.125 mM Tris-HCl, pH 6.8, 5 % sodium dodecyl 
sulphate (SDS) [w/v], 20 % glycerol [w/v], 0.002 % bromophenol blue, 10 % 2-
mercaptaethanol) and heated at 100°C for 5 minutes for denaturation. The denatured 
protein samples were then separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) in 10 % gel using a mini-gel apparatus (Bio-Rad, 
USA). Proteins were loaded at 15 fag per lane. The gels were run at lOOV constant 
voltage per slab for about 2 hours. Protein molecular weight markers were obtained 
from Bio-Rad Laboratories. For further confirmation of equal protein loading, gels 
were stained with Commassie blue. The gels were submerged in a 0.2 % Commassie 
blue staining solution (0.2 % Commassie blue in destaining solution) for about 10 
minutes. The stained gels were washed in a destained solution (methanol: glacial 
acetic acid: distilled water, 3:1:6 v/v). 
After electorphoresis, gels were fixed in a transfer buffer containing 25 mM 
Tris, 192 mM glycine and 10 % methanol, pH 8.3, for 30-45 minutes. Proteins were 
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electrophoretically transferred onto the PVDF membranes (0.20 |im，Schleicher & 
Schuell) in the transfer buffer at lOOV at 4°C for 1 hour. The blotted membranes 
were blocked with 1 % Tween-20 in PBS for 1 hour and then washed in a washing 
buffer containing 0.05 % Tween-20 in PBS, for 30 minutes. The primary antibodies 
for hormone receptors were first diluted 1:1000 in PBS with 2.5 % non-fat milk 
powder. The membranes were subsequently incubated with the diluted antibody 
overnight at room temperature on a rocking platform. For control blots, membranes 
were incubated in 2.5 % non-fat milk in PBS without primary antibodies. After 
overnight incubation, membranes were washed with the washing buffer, followed by 
a one-hour incubation with the alkaline phosphatase-conjugated secondary antibody 
diluted 1:2000 in PBS with 2.5 % non-fat milk powder at the room temperature. 
After washing, the antibody binding sites on the blotted membranes were detected by 
a colorimetric method. The membranes were first incubated in a substrate buffer 
(100 mM Tris, 100 mM NaCl and 50 mM MgCb, pH 9.5) for 10 minutes. The color 
reaction was developed by incubation in a chromogen solution containing 45 |j.l 
nitroblue tetrazolium (NBT, 75 mg/ml in dimethylformamide), 35 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP, 50 mg/ml in dimethylformamide) and 0.24 
mg/ml levamisole (1 mM) in 10 ml substrate buffer at 25°C for several minutes. The 
color reaction was stopped by incubating in a stop buffer (10 mM Tris, 1 mM 
EDTA, pH 8.0) and then rinsed with running tap water. The color-developed 
membranes were finally dried with blotting paper. 
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Chapter 3. Results 
3.1 Gross Appearance of Mammary Tumors 
The rat mammary tissues extend from the auxiliary to the inguinal region and 
are distributed in pairs on either side of the ventral midline. There are totally six 
pairs of mammary glands. One pair of mammary gland can be found in the cervix, 
another two pairs in the thorax and abdomen respectively, and the remaining pair is 
located in the inguinal region (Figure 3.1.1 A). Each mammary gland extends from 
the medially located nipples in the dorsolateral orientation (Figure 3.1.IB). 
According to our results, mammary tumors could develop in Noble rats 
spontaneously or be induced by the hormonal or carcinogenic stimulations. The 
tumors could be found in any area of the mammary tissue. No particular tendencies 
for the localization of the mammary tumors on the animal were observed. In each 
tumor-bearing animal, more than one mammary tumor generally could be found. The 
neoplasm usually distributed singly in each mammary gland. However, in some 
cases, the tumors would arise in different positions of the same mammary gland. 
Grossly, mammary tumors appeared as palatable lump in the mammary areas 
of the animals. Usually, they were firm, soft and smooth masses and were freely 
moveable in the subcutaneous tissue. 
Mammary tumor could attain to huge size, occasionally could be as large as 
about half of the body weight of the animals. Gross dissection revealed that the large 
tumor often became necrotic and infected in the core region. The large tumor would 
also disrupt the ability of the animal to move around or even to eat. This further 
contributed to the debility and even mortality of the animals 
Usually, but not always, there were some differences in the gross 
appearances of the mammary tumors under different treatments. Gross dissection 
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revealed that the incidence of spontaneously developed mammary tumors in Noble 
rats was usually associated with a plenty of milk secretion in the mammary tissues. 
The milk secretions usually appeared in the form of white patches in the mammary 
areas surrounding the tumors (Figure 3.1.2A). In some case, milk secretions could 
also be found inside the tumor. Apart from the mammary areas adjacent to the 
tumor, the milk patches also appeared in other mammary glands even tumors were 
not found in those areas. Generally the spontaneously developed mammary tumors 
are white in color, rubbery and firm in gross appearance. The neoplasic tissues 
usually shells out from the main mass when the tumor was being dissected. 
On the other hand, the mammary tumors induced by the carcinogen DMBA 
and NMU rarely associated with the incidence of milk secretions (Figure 3.1.2B). 
The tumors generally appeared as solid masses and could be sectioned easily. In 
some cases, areas of necrosis and haemorrhage were encountered. 
For the hormone induced mammary tumors, both the T+E2 and T+DES 
induced group gave similar gross appearances. In comparison, the hormone induced 
mammary tumors were relatively small in size and difficult to discover. The 
hormone treated animals were usually moribund when the mammary tumors were 
palpable. In most cases, multiple prominent black lesions were found in the 
mammary areas nearby the tumors (Figure 3.1.2C). Occasionally, these lesions were 
located in glandular areas far away from the neoplasm. Gross dissections revealed 
that these black lesions were cystic structures containing blood and necrotic 
materials. The hormone-induced mammary tumors were also filled with fluids. In 
some case, the incidence of the hormone induced mammary tumors was associated 
with the abnormality of other organs. The female sex organs, uterus and ovary, were 
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frequently involved. Occasionally, the liver and lung of the animal were also 
affected. ‘ 
3.2 Incidence Rate of Mammary Tumors 
3.2.1 Spontaneously Developed Mammary Tumors in Noble Rats 
Totally 40 female and 32 male Noble rats were remained intact and used as 
control animals for the experiment. In this control group, 27 mammary tumors were 
collected from 18 female (Table 3.1). One mammary tumor was also collected from 
the male rat. The incidence rate of the spontaneously developed mammary tumors in 
the female Noble rat was 45% while that of the male animals was 3.13%. The 
average age of the Noble rat for the incidence of spontaneous mammary neoplasm 
was 14-months-old. The incidence of the breast tumors was rare when the age of the 
animal was less than 12-months-old. Figure 3.2.1 showed a cumulative incidence of 
spontaneous mammary tumors in female Noble rats against the age of the animals. 
3.2.2 Hormone Induced Mammary Tumors in Female Noble Rats 
The incidence rate, latency period and distribution of the hormone induced 
mammary tumors in female Noble rats were given in table 3.2, 3.3 and 3.4. 
For the testosterone and 17p-estradiol (T+E2) treatment group, the mortality 
rate of the hormone treated Noble rats was 25% and the incidence rate of the 
“ hormone induced tumor was 46.66%. On the other hand, for the testosterone and 
Diethylstilbestrol (T+DES) group, the mortality rate was 55% and the incidence rate 
was 55.55%. In comparison, the mortality of T+DES group was more than twice the 
value of the T+E2 group. The incidence rate of the T+DES induced mammary 
tumors was also higher than that of the T+E2 group. However, the average latency 
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period for the incidence of the T+ DES induced tumors was little bit longer than that 
of the T+E2 treatment, as 10 months compared with 8.86 months. 
3.2.3 DMBA Induced Mammary Tumors in Female Noble Rats 
In comparison, the latency period for mammary tumorigenesis in the 
carcinogen induction group was relatively short. The first palpable mammary tumor 
was found in the treated animals only after 2 months of the chemical carcinogenic 
treatment. The mean latency period for development of mammary tumor was 6.38 
months. The overall incidence of breast tumors was as high as 80%. 
- Figure 3.2.1 showed a comparison of the incidence rate and latency period of 
mammary tumorigenesis between the carcinogen and hormone treatment in female 
Noble rats. 
3.2.4 NMU Induced Mammary Tumors in Female SD Rats 
The incidence rate of NMU-induced mammary tumors in female SD rats was 
as high as 100%. The mean latency period for the mammary tumorigenesis was 6 
months. Generally, more than one mammary tumor could be found from the treated 
animals. These tumors might be collected form the cervical, thoracic, abdominal or 
inguinal mammary glands of the animals. No particular tendency for the localization 
of the induced breast tumors was observed. 
3.3 Histology of Normal and Lactating Mammary Glands in 
Female Noble Rats 
Mammary glands in sexually mature virgin Noble rat were characterized by a 
sparse distribution of terminal end buds, alveolar buds and ductal systems in a large 
amount of adipose tissues (Figure 3.3.1). The club-shaped terminal buds were lined 
by a thick epithelium composed of five to ten layers of cells (Figure 3.3.1 A). The 
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alveolar buds were small in size and appeared as clusters of alveolar tubules. The 
tubules only possessed narrow lumen (Figure 3.3.IB). The mammary ducts also had 
small lumen. The ductal epithelium was lined by cuboidal cells of one layer thick 
and was embedded in a small amount of connective tissue (Figure 3.3.IC). Due to 
their large size, the epithelial tubules were very easy to discover in the stromal 
tissue. 
In the lactating mammary glands, both the terminal end buds and alveolar 
buds decreased in number significantly (Figure 3.3.2). It was due to the 
differentiation of the terminal buds into alveolar buds, which further differentiated 
into lobules. The lactating gland is fundamentally composed of the lobular 
structures. The lobular structures were large in size. They were composed of 
increased number of individual alveolar structures. The alveolar structures possessed 
wide lumens (Figure 3.3.3). 
3.4 Histopathology of Mammary Tumors 
3.4.1 Histopathology of Spontaneously Developed Mammary Tumors in Noble 
Rats 
Of the 26 spontaneously developed mammary tumors collected from 17 
female Noble rats (Table 3.1), histopathological examinations revealed that most of 
them (80.77%) are benign neoplasm. In the male Noble rat, only one sample of -
benign fibroadenoma was collected. 
The vast majority of the spontaneous tumors collected from the Noble rat 
colony were fibroadenoma, which comprise 70.37% of all the mammary neoplasms 
discovered. The malignant carinoma only comprises of 18.2% of all the spontaneous 
mammary tumor collected from Noble rats. 
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Mammary areas nearby the tumor were also collected for histopathological 
examination. Preneoplastic changes were often encountered in these areas, ranging 
from lobular hyperplasia to atypical hyperplasia. The early preneoplastic change in 
mammary gland, namely lobular hyperplasia, was characterized by the lobule 
enlargement (Figure 3.4.1 to 3.4.3). The enlarged lobules were consisted of 
relatively normal alveoli. The alveoli increased in both number and size. In some 
cases, the alveoli were filled with proteinaceous secretion that might contain lipid 
droplets. Cystic changes were also observed (Figure 3.4.8). The alveolar and ductal 
systems were dilated. The distended lumens were filled with granular materials 
composed of lipids and proteinaceous materials. On the other hand, the late 
preneoplastic changes in the mammary gland were characterized by the incidence of 
atypical hyperplasia. Focal irregular proliferations of epithelium were observed 
within the mammary ducts or alveoli (Figure 3.4.4 to 3.4.7; Figure 3.4.9 & 3.4.10). 
The focal proliferation may be appeared in the form of papillary infolding, arches, 
solid nests or plagues which extended into the lumen from the epithelial layer. 
The commonly encountered spontaneously developed fibroademona in Noble 
rats were composed of both connective tissues and mammary epithelial cells (Figure 
3.4.11 to 3.4.16). The proportion of these two cells types varied from sample to 
samples. In some case, the fibroadenoma was composed almost entirely of 
connective tissue. However, occasionally, the tumor was mainly epithelial. The 
histopathology of the fibroadenoma also varied in the secretory behaviors. In some 
cases, the alveolar lumina were dilated and contained secretory materials. Lipid 
vacuoles might also present in the epithelium cytoplasm. Nevertheless, in other case, 
the ductular epithelium was attenuated or atropic. No secretory material was found in 
the narrow ductal or alveolar lumens. 
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The histopathology of the fibroadenoma was highly heterogenous. The same 
tumor might show deviated histopathology. The histopathologic! heterogeneity was 
observed even in the identical microscopic field (3.4.15). 
The other rare benign neoplasms that were collected from female Noble rats 
included pure fibromas and adenomas. The spontaneously developed fibroma 
consisted entirely of collagen fibers (Figure 3.4.17). Fibroblasts, arranged in 
interlacing bundles, were occasionally embedded in the collagen fibers (Figure 
3.4.18). Pure adenoma was another rarely encountered spontaneously developed 
benign neoplasm in Noble rats. The tumor was composed entirely of glandular 
epithelial structures with a scant connective tissue stroma. The alveoli and ductules 
were widely distended by proteinaceous secretory material. Cytoplasmic 
vacuolization was also observed in the alveolar epithelial cells (Figure 3.4.19 & 
3.4.20). 
In some neoplastic samples developed naturally in Noble rats, there were 
areas that the alveolar or ductal lumens were partially or completely filled by the 
tumor cells. These were referred as carcinoma in situ. Figure 3.4.21 to Figure 3.4.26 
showed some examples of the carcinoma in situ, ranging from papillary, cribriform 
or comedo patterns, which might occur alone or in combination in the neoplastic 
areas. 
In the papillary carcinoma, the ductal structures were dilated and the lining 
epithelium grew inward to form epithelial papillae. The papillae possessed thin 
fibrovascular core (Figure 3.4.21 & 3.4.22). Occasionally, the papillae might possess 
cystic properties (Figure 3.4.23 & 3.4.24). In such cases, the papillae were observed 
projecting towards the cystic cavity. The fibroconnective tissue in the papillary core 
was edematous and was infiltrated by lymphoytes. Cell detritus could also be found 
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in the edematous core. On the other hand, the cribriform pattern was characterized 
by neoplastic cells which extended into the ductal' lumen to from bridges of 
anastomosing arcades with many vacuole-like structures (Figure 3.4.25). Comedo 
carcinomas were lesions appeared as distended ductal structures lined by a 
multilayered epithelium surrounding central necrotic debris (Figure 3.4.26). 
As the tumors continued to develop, they invaded the stroma, forming the 
infiltrating ductal or lobular carcinoma. The infiltrating ductal carcinoma could be 
- developed from the papillary, cribriform or comedo carcinoma in situ (Figure 3.4.30; 
3.4.32; 3.4.34 to 3•4.40). A sample of infiltrating tubular carcinoma was also 
collected from the Noble rats. Figure 3.4.27 to 3.4.32 showed the histopathological 
comparisons between the tubular carcinoma and papillary carcinoma. The tubular 
pattern was observed as lesion consisted of closely packed and elongated tubular 
structures (Figure 3.4.27). The lumina of the tubular structures were generally empty 
and narrow (Figure 3.4.29). Occasionally, secretions were observed in the alveolar 
lumina (Figure 3.4.31). 
Figure 3.4.33 to figure 3.4.38 demonstrated some examples of the infiltrating 
ductal carcinoma of the cribriform, comedo and papillary patterns. These tumors 
were still well-differentiated and all retained the tendency to form tubules and 
alveoli. On the other hand, figure 3.4.39 to figure 3.4.44 illustrated examples of the 
poorly differentiated carcinomas. These tumors were characterized by areas of poor 
cellular organizations virtually devoid of glandular formation. These carcinoma cells 
commonly appeared as isolated islets infiltrating the surrounding connective tissues, 
adipose tissues or skeletal muscles. In these situations, the tumor was called an 
anaplastic carcinoma. Figure 3.4.47 showed a histopathological transition of a 
carcinoma from a relatively well-differentiated type into an anaplastic carcinoma. 
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In some cases, the incidence of spontaneous mammary tumors in Noble rat 
was associated with the abnormalities of the other peripheral organ, including liver 
and lung. Grossly, the abnormality of lung was appeared as the presence of obvious 
white patches on the surface of the organs. Figure 3.4.45 & 3.4.46 showed a 
histological examination of the apparently abnormal lung tissues. The alveolar lining 
was clearly thickened. This abnormal thickening might be due to the deposits of 
metastastic cancer cells from the mammary origins. 
The histopathology of the spontaneously developed mammary tumors in 
Noble rats was highly heterogenous. The tumor histopathology often differed from 
portion to portion within the same tumor, and it was not uncommon that more than 
one histopathological type could be found within the same microscopic field (Figure 
3.4.48 to 3.4.53). 
3.4.2 Histopathology of Hormone Induced Mammary Tumors in Female 
Noble Rats 
Both the T+E2 and T+DES-induced mammary carcinomas gave similar 
morphological appearances. The early histological changes in the hormone-treated 
mammary glands were characterized by the formation of enlarged cystic lobules 
(Figure 3.4.54 & 3.4.55). The histology of Individual alveolus of the lobule was 
relatively normal. The alveoli were lined by a single layer of low cuboidal 
epithelium. Their lumens were distended and filled with secretory materials. In some 
case，vacuolization was observed in the cytoplasm of the alveolar epithelial cells. 
Stroma surrounding the cystic alveoli was composed of normal adipose cells 
(3.4.56). 
Subsequent hormonal treatment resulted in epithelial hypertrophy and 
hyperplasia. The contour of the alveolus was irregular. The epithelium tended to 
59 
grow inward and fill the cystic lumen (Figure 3.4.56 & 3.4.57). The abnormal 
intraductal epithelial proliferation finally resulted in the formation of the intraducal 
carinoma. The carcinoma might be in the pathological classification of the papillary 
pattern, cribriform pattern or the comedo pattern (Figure 3.4.58 & 3.4.59). 
Very often, the hormone-induced carcinoma appeared as clusters of detached 
neoplastic epithelial cells floating on a distended cystic lumen (Figure 3.4.60 & 
3.4.61). The core region of the detached carcinoma islets was usually composed of 
edematous fibroconnective tissues. Infiltration of lymphocytes was sometimes 
observed. 
3.4.3 Histopathology of DMBA Induced Mammary Tumors in Female Noble 
Rats 
The mammary neoplastic samples induced in female Noble rats by the 
administration of the carcinogen DMBA were all classified as carcinomas. 
Carcinoma of papillary, cribriform and comedo patterns were collected. Figure 
3.4.62 to 3.4.64 showed some representative photomicrographs of the histopathology 
found in the DMBA induced mammary tumors. In some areas of the invasive 
neoplastic samples, anaplastic carcinoma was found. The carcinoma cells appeared 
as clusters of epithelial cells embedded in the stromal tissues (Figure 3.4.65). 
3.4.4 Histopathology of NMU Induced Mammary Tumors in Female SD Rat 
Carcinomas of various histopathological types were collected from the 
NMU-treated SD rats. The carcinomas ranged from papillary, cribriform to comedo 
patterns. These histopathological types might appear alone or in combinations. 
Occasionally, anaplastic carcinoma was also observed. 
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3.5 Whole Mount Preparation of Mammary Glands under 
Hormonal Treatments 
Whole mount preparation of virgin female Noble mammary gland was 
characterized by numerous sparsely distributed lateral alveolar buds on a long 
narrow mammary duct. Terminal end buds could be found at the end of the terminal 
ducts (Figure 3.5.1). Both the lateral and terminal buds were small in size. Only low 
degree of differentiation was observed. 
10 days after the simultaneous testosterone and 17-f3 estradiol treatment, high 
degree of lobuloalveolar differentiation was observed (Figure 3.5.2). There was _ 
prominent lobule formation. The lateral alveolar buds increased significantly in both 
the number and size. They were often cyst filled. The mammary ducts were also 
thickened. The terminal end buds were no longer found on the ending of the terminal 
mammary ducts due to its differentiation to form alveolar buds. 
2 months post the combined hormonal treatments, further lobuloalveolar 
differentiation was observed (Figure 3.5.3). The lateral alveolar 'buds increased 
further in number and size. Large cystic buds were frequently encountered in the 
whole mount specimens. 
3.6 Effects of Bilateral Ovariectomy on the Growth of 
Spontaneously Developed Mammary Tumors 
Bilateral ovariectomy was carried out on three individual Noble rats bearing 
palpable spontaneously mammary tumors. Table 3.5 showed the changes in the 
volume of the spontaneously developed mammary tumors in the bilateral 
ovariectomized Noble rats. 
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Figure 3.5 demonstrated the growth rate of the spontaneously developed 
mammary tumors after bilateral ovariectomy. The alternations in the hormonal 
environment by surgical removal of sexual gland generally accompanied by the 
initial retarded growth of the mammary tumors. Thereafter the mammary tumors 
continued to grow. Regression of the spontaneously developed mammary tumors 
was not observed after bilateral ovariectomy. 
3.7 Transplanability of the Spontaneously Developed Mammary 
Tumors in Noble Rats “ 
In order to establish a transplantable tumor line, some of the spontaneously 
developed mammary tumors collected from the female or male Noble rats were 
transplanted to other individual rats of the same species and sex. Table 3.6 showed 
the details of the transplanted spontaneously developed mammary tumors. 
Histopathological examinations revealed that all the transplanted tumors 
were benign fibrodenomas (Figure 3.7.1 to 3.7.3). They were all being successfully 
transplanted to the host Noble rats. Generally, the tumor transplants needed 4 
months，time to become a palpable mass in the host animals. The tumors were then 
transplanted to other Noble rats to generate subsequent generation of transplanted 
tumor line. So far, the transplanted tumor lines were in the third generations. 
3.8 Examination of the Malignancy of Mammary Tumors by 
Immunohistochemical analysis of Epithelial Keratin Expression 
To investigate the invasiveness of the mammary tumors into the adjacent 
stromal tissue, immimohistochemisty of a broad spectrum of keratin was carried out. 
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Some representative photomicrographs were selected to demonstrate the keratin 
expression in the epithelial cells of the normal Noble mammary gland and 
spontaneously developed mammary neopalsms (Figure 3.8.1 to 3.8.8). 
The cytoplasm of the normal mammary epithelial cells was positively stained 
for keratins (Figure 3.8.1). The strong cytoplasmic expression was reserved in both 
the benign neoplasim and carcinoma in situ (Figure 3.8.2 to 3.8.4). Figure 3.8.5 to 
3.8.8 showed some examples of the highly malignant mammary carcinoma. Clusters 
of epithelial cells positively stained with cytokeratin were observed invading the 
surrounding stromal tissues. 
3.9 Immunohistochemical Analysis of Expression and Localization 
of Hormone Receptor Protein in Normal and Neoplastic Mammary 
Tissues of Female Noble Rats 
3.9.1 Expression and Localization of Hormone Receptors in Control Tissue 
Uteri samples were collected from adult virgin Noble rat and used as a 
positive control tissue for the estrogen receptor a (ERa), estrogen receptor p (ERP) 
and progesterone receptor (PR). The specificity of the staining was established by 
omitting the primary or secondary antibody. Figure 3.9.1 showed a negative control 
sample from a uterus section. In the control sample, primary antibody was omitted 
and no immunoreactivity was detected. 
Figure 3.9.3 to 3.9.8 showed some Noble rat uterine samples stained for the 
ERa (Figure 3.9.3 & 3.9.4)，ERp (Figure 3.9.5 & 3.9.6) and PR (Figure 3.9.7 & 
3.9.8). For the ERa and ERp, strong nuclear staining was observed in most 
endometrial and stromal cells. Strong nuclear ERp staining was also observed in the 
muscle layers. For the PR, strong nuclear staining was observed in endometrial cells. 
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However, the stromal and muscle cells only exhibited a moderate level of staining. 
These results matched well to the published data (Wang H et al, 1999). 
For the androgen receptor (AR), adult Noble rat prostate was used as a 
control tissue. In the rat prostate, strong AR immunoreactivity was observed in the 
cytoplasm and unclei of the glandular epithelail cells (Figure 3.9.28). The specificity 
of the positive signal was evaluated by omitting the primary antibody on the control 
samples. The heavy AR staining was no longer observed (Figure 3.9.27). 
For the prolactin receptor (PRLR), lactating mammary glands and livers of 
female Noble rat were used as the control tissues. In the lactating mammary glands, 
strong PRLR expression was detected in the cell membranes of the alveolar 
epithelial cells. Sometimes, moderate cytoplamic PRLR immunostaining was also 
observed in the epithelium (Figure 3.9.30). In the liver tissues, PRLR 
immunoreactivity was localized in cell membranes and cytoplasmic granules of the 
hepatocytes (Figure 3.9.32). The specificity of the immunostaining was tested by 
omitting the primary antibody on the control tissues. No significant 
immunoreactivity was detected in both livers and lactating mammary glands of the 
negative control staining (Figure 3.9.29 & 3.9.31). 
Table 3.7 showed a summary of the immunohistochemical analysis of the 
expression intensities in various hormone receptor proteins in normal and neoplastic 
mammary tissues in female Noble rats. 
3.9.2 Expression and Localization of Estrogen Receptor a 
Immunohistochemical staining for ERa in normal female mammary glands 
revealed that most ductal and alveolar epithelial cells had strong nuclear staining. 
Figure 3.9.9 showed a terminal end buds heavily stained for the ERa in the nuclei of 
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most epithelial cells. When the primary antibody was omitted, no immunoreactivity 
was observed (Figure 3.9.2). 
Mammary tumors of different experimental groups also showed a positive 
nuclear immunoreactivity for ERa. However, a derivation of the expression intensity 
was observed. In the spontaneously developed mammary tumors, a consistent strong 
nuclear staining was observed in both benign (Figure 3.9.10) and malignant 
neoplasms (Figure 3.9.11). In the DMBA-induced mammary tumors, only a weak to 
moderate nuclear immunostaining was observed (Figure 3.9.12). On the other hand，-
the hormone-induced mammary tumors, either from T+E2 (Figure 3.9.13) or T+DES 
treatment (Figure 3.9.14), exhibited a moderate to strong nuclear immunoreactivity. 
3.9.3 Expression and Localization of Estrogen Receptor p 
Immunohistochemical analysis of ERp in normal female mammary gland 
revealed that a moderate cytoplasmic and nuclear staining was observed in most 
ductal or alveolar epithelial cells (Figure 3.9.15). In the mammary tumors, the 
expression of ERp is varied (Figure 3.9.16 to 3.9.20). In the spontaneously 
developed mammary tumors, weak cytoplasmic staining was observed in the benign 
neoplasm (Figure 3.9.16). However, in the malignant carcinoma, a moderate 
cytoplasmic immunoreactivity was detected (Figure 3.9.17). In contrast, mammary 
tumors induced by DMBA only exhibited a very weak ER(3 immunostaining (Figure 
3.9.18). For the hormone induced mammary tumors, a strong cytoplasmic ERp 
staining was observed in both the T+E2 (Figure 3.9.19) and T+DES (Figure 3.9.20) 
induced mammary carcinomas. 
3.9.4 Expression and Localization of Progesterone Receptor 
Immunohistochemisty of PR showed that the normal mammary ductal and 
alveolar epithelial cells only exhibited a moderate nuclear and cytoplasmic 
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immunoreactivity (Figure 3.9.21). In the spontaneously developed mammary tumors, 
a strong nuclear PR staining was observed in both benign tumors (Figure 3.9.22) and 
malignant carcinomas (Figure 3.9.23). On the other hand, moderate to strong nuclear 
immunoreactivity was also observed in DMBA-induced mammary carcinomas 
(Figure 3.9.24). In the T+E2 induced mammary carcinoma, a moderate cytoplasmic 
and nuclear PR staining was observed (Figure 3.9.25). However, mammary 
carcinoma induced with T+DES exhibited a strong nuclear staining (Figure 3.9.26). 
3.9.5 Expression and Localization of Androgen-Receptor 
Immunohistochemical staining for AR in normal female mammary glands, 
revealed that most ductal and alveolar epithelial cells only showed a moderate 
cytoplasmic immunostaining to AR (Figure 3.9.33). In contrast, more intense AR 
immunoreactivity was observed in the mammary tumors. In the spontaneously 
developed benign mammary tumors, strong cytoplasmic and nuclear staining was 
observed in the alveolar epithelium (Figure 3.9.34). The heavy nuclear AR staining 
was reserved in the spontaneously developed malignant neoplasms (Figure 3.9.35). 
In the DMBA-induced mammary tumors, only moderate AR nuclear 
immunostaining was observed in the carcinoma cells (Figure 3.9.36). The hormone-
induced mammary tumors, either from T+E2 (Figure 3.9.37) or T+DES treatment 
(Figure 3.9.38), exhibited a moderate to strong cytoplasmic and nuclear 
immunoreactivity. 
3.9.6 Expression and Localization of Prolactin Receptor 
Immunohistochemical analysis of PRLR in normal female mammary gland 
revealed that only a weak to moderate cytoplasmic staining was detected in the 
alveolar epithelial cells (Figure 3.9.39). In the spontaneously developed adenomas, 
strong PRLR immunoreactivity was observed in the plasma membrane and 
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sometimes in the cytoplasm of the most epithelial cells (Figure 3.9.40). The intense 
cell membrane and cytoplasmic PRLR immunoreactivity was also detected in the 
spontaneously developed carcinoma cells (Figure 3.9.41). Similarly, mammary 
tumors induced by DMBA also exhibited strong PRLR immunostaining in focal 
areas (Figure 3.9.42). For the T+E2 induced mammary tumors, only weak to 
moderate PRLR immunoreactivity was observed (Figure 3.9.43). In contrast, 
carcinoma induced by T+DES exhibited strong PRLR immunoreactivity (Figure 
3.9.44). 
3.10 Western Blot Analysis of Expression of Hormone Receptor 
Proteins in Normal and Neoplastic Mammary Tissues of Female 
Noble Rats 
3.10.1 Expression of Estrogen Receptor a 
Western Blot analysis ofERa identified several bands on SDS-PAGE at �67， 
54 and 50 kDa in Noble rat uteri (Figure 3.10.1). Mammary samples from untreated 
female Noble rats exhibited a very low expression of the 67 kDa native ERa protein. 
The expression of the 67 kDa protein was uplifted in the spontaneously developed 
benign and malignant mammary tumors. In the spontaneously developed neoplastic 
samples, an expression of the 54 kDa putative ERa was detected. In the 
spontaneously developed carcinoma, there was a further expression of the 50kDa 
putative ERa. In the DMBA induced carcinoma, an expression of the 67 kDa native 
and 50kDa putative ERa protein was detected. Mammary carcinoma induced by 
combined hormonal treatment, either T+E2 or T+DES exhibited an intense 
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expression of the 67kDa ERa protein. Expression of other putative ERa protein was 
not detected. 
3.10.2 Expression of Estrogen Receptor p 
Western blot analysis of ERp in Noble rat uteri detected an expression of �5 5 
kDa ERP protein (Figure 3.10.2). A very low expression level of ERp was also 
detected in normal female Noble rat mammary glands. A marked increase of ERp 
expression level was observed in the spontaneously developed mammary tumors. In 
comparison, the spontaneous carcinoma exhibited higher protein expression intensity 
thah the spontaneous benign lesions. In the carcinogen or hormone induced 
mammary carcinoma, expression of 55kDa ERp protein was not detected. 
3.10.3 Expression of Progesterone Receptor 
Western blot analysis of Noble rat uteri detected the presence of several PR 
isoforms (Figure 3.10.3). In the uteri samples, high expression of �82kDa PR-A2 
and moderate expression of �98kDa PR-Al and � 6 4 kDa PR-C were observed. In 
normal female Noble mammary gland, the strong expression of PR-A2 remained. A 
low expression of PR-C isoform was also detected. Benign mammary tumors 
developed spontaneously in Noble rats exhibited a moderate expression of PR-A2 
protein. The expression level of PR-C isoform in the benign lesions was comparable 
to that of the normal mammary glands. In the spontaneously developed carcinoma, 
both the expression of PR-A2 and PR-C was obviously elevated. A further 
expression of the �116kDa PR-B and -98 kDa PR-Al was also observed in the 
spontaneous carcinoma samples. In other carcinoma samples induced by either 
DMBA or combined hormonal treatment, there was a consistent high expression of 
PR-A2 protein. When compared with the spontaneously developed carcinoma, the 
expression of PR-C protein was reduced. Both the DMBA and T+E2 induced 
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carcinoma showed a low expression ofPR-C protein whereas in the T+DES induced 
carcinoma, expression of PR-C was not detected. . 
3.10.4 Expression of Androgen Receptor 
AR protein was not detected in western blot analysis of the receptor in female 
Noble mammary glands (Figure 3.10.4). In the spontaneously developed benign 
mammary tumors, a weak expression of both AR-A (�97kDa) and AR-B (~116kDa) 
proteins were detected. A further elevation of the � 9 7 and �116 kDa AR protein 
expression was observed in the spontaneously developed mammary carcinomas. In 
the DMBA induced mammary carcinoma, only an expression of 97kDa AR-A 
protein was detected. In the hormone induced mammary carcinomas, the presence of 
AR-A protein was also observed. However, its expression was much weaker than the 
carcinogen induced carcinomas. Expression of the AR-B protein was not detected in 
both the T+E2 and T+DES induced neoplasms. 
3.10.5 Expression of Prolactin Receptor 
Noble rat liver was used as a control tissue to evaluate the expression of the 
long form and short form prolactin receptor protein on the SDS-PAGE. It was 
known that both receptor isoforms could be found in the liver although the short 
form represented the dominant species. Western blot analysis of PRLR identified a 
strong expression of �40kDa PRLR protein on the liver tissue. This ~40kDa protein 
was considered as the short form prolactin receptor. Expression of the short PRLR 
isoform was not detected in the other normal or neoplastic mammary tissues. 
On the other hand, a weak expression of a PRLR protein with molecular size 
about 65kDa was also detected on the liver tissues. This was regarded as the long 
PRLR protein. Expressions of the long isoform were detected in all normal and 
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neoplastic mammary samples, including the spontaneously developed, honnone-
induced and carcinogen-induced mammary tumors. 
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Figure 3.1.1 Schematic Representations of the Locations of the Six Pairs of Rat 
Mammary Glands. ’ 
(A) Ventral View of the Rat Mammary Glands. The rat's mammary glands are 
distributed in pairs along the milk line, with one pair located in the cervix, two in the 
thorax, another two in the abdomen and one in the inguinal regions. 
(B) Lateral View of the Rat Mammary Gland. The nipples of the mammary gland 
are medially located and from there the mammary ductal system extends 
subcutaneously and dbrsolaterally into the mammary fat pads. 
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Figure 3.1.2 Gross Appearance of Mammary Tumors Under Different Treatments in 
Female Noble Rats. 
(A) Spontaneously Developed Mammary Tumor. Milk secretions, which appeared in 
the form of white patches (indicated by arrows), were frequently observed in 
mammary areas nearby the tumors. 
(B) DMBA-Induced Mammary Tumor. Mammary tumor induced by carcinogens 
usually appeared as a solid mass. 
(C) Hormone-Induced Mammary Tumor. Black liquid lesions (indicated by arrows) 
were commonly found in mammary areas near or far away from the hormone-










































































































































































































































Figure 3.3.1 Histology of Rat Normal Mammary Gland. In adult virgin rats, the 
inactivated mammary glandular structures were surrounded by large amount of 
fibrous and adipose tissues. Terminal end buds (TEB), alveolar buds (AB) and ductal 
structures were sparsely distributed in the stroma. 
(A) Terminal End Bud (TEB). TEB was composed of several layers of epithelial 
cells surrounding a narrow lumen. -
(B) Alveolar buds (AB). ABs appeared as clusters of 3-5 tubules, each having a 
centrally located lumen surrounded by a layer of cuboidal epithelial cells. 
(C) Duct. The epithelial component of the duct was composed of an inner luminal 
epithelial layer surrounded by myoepithelial cells. The duct was separated from the 
surrounding mesenchymal cells and connective tissues by the basement membrane. 
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Figure 3.3.2 Histology of Female Rat Normal Mammary Gland (left) and 
Lactating Mammary Gland (right). The glandular area increased significantly in the 
lactating mammary gland. The lactating gland was composed mainly of the enlarged 
lobular structures. TEBs fundamentally disappeared due to their differentiation into 
the lobular structures. 
Figure 3.3.3 Higher Magnification of the Lobular Structure in the Virgin 
Mammary Gland (left) and Lactating Mammary Gland (right). The lobular _ 
structures in the lactating gland were enlarged and composed of more and larger 
individual alveolar structures. 
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Figure 3.4.1 - 3.4.6 Non-Neoplastic Lesions. The figures showed a series of pre-
neoplastic changes of a mammary gland from lobular hyperplasia into atypical 
hyperplasia. 
Figure 3.4.1 Lobular Hyperplasia with Cystic Changes. Lobular hyperplasia 
consisted of enlarged lobules of relatively normal appearing alveoli. The alveoli 
increased in number and size, and were usually filled with proteinaceous secretion 
containing lipid droplets. Large ductal cysts could also be found from the figure. 
Figure 3.4.2 Severe Lobular Hyperplasia. The gland was mainly composed of 
enlarged lobule. 
Figure 3.4.3 Higher Magnification of Alveoli in Hyperplastic Lobules. The 
histology of the alveolar epithelial cells was still appearing normal. The alveolar 
epithelium was one cell thick and cuboidal in shape. Individual alveolus within the 
lobule was separated by a thin layer of connective tissues. 
Figure 3.4.4 Early Atypical Hyperplasia. Atypical hyperplasia consisted of focal 
irregular epithelium proliferation within ducts or alveoli. The arrow indicated a 
hyperplasic epithelium extending into the cystic ductal lumen. 
Figure 3.4.5 Mild Atypical Hyperplasia. The arrow showed a mild epithelial 
hyperplasia found in the arch of a ductal cyst. Epithelium besides the hyperplasic 
cells was still one cell thick. 
Figure 3.4.6 Severe Atypical Hyperplasia. The arrow indicated a severe epithelial 
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Figure 3.4.7 Lobular Hyperplasia and Atypical hyperplasia. The stomal area was 
essentially occupied with enlarged lobules. Individual "alveolar unit was filled with 
proteinaceius secretion. Hyperplasic alveolar and ductal epithelium was also found. 
Figure 3.4.8 Cysts. Cysts were common non-neoplastic structures found in the 
mammary gland. They might arise from either ductal or lobular elements. Secretory 
materials were usually found in the distended cystic lumen. 
Figure 3.4.9 & 3.4.10 Atypical Hyperplasia. Hyperplasic epithelial plaques extended 
into the cystic ductal lumen (black arrows). 
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Figure 3.4.11 - 3 A16 Benign Neoplasms. 
Figure 3.4.11 Fibroadenoma. The figure showed a fibroadenoma developed 
spontaneously in an aged male Noble rat. The tumor consisted of concentric layers 
of dense connective tissue with a small number of widely dispersed ductules. 
Figure 3.4.12 Fibroadenoma. The figure showed a fibroadenoma collected from an 
aged female Noble rat. The alveoli within the lobule were secretory. Lipid vacuoles 
were also observed in the alveolar cytoplasm. Connective tissue distributed within 
and between the lobules. 
Figure 3.4.13 Ductules in Male Noble Fibroadenoma. The ductular epithelium was 
attenuated and atrophic. Individual ductle was widely separated by concentric layers 
of connective tissue. 
Figure 3.4.14 Secretory Alveolar Epithelium in Female Fibroadenoma. Lipid 
vacuoles were present in the alveolar epithelium cytoplasm. The alveolar lumina 
were dilated and contained secretory material. 
Figure 3.4.15 Heterogeneity of Mammary Tumor Histopathology. Progressive 
change in the histopathology of a fibroadenoma from non-seretory tubular pattern 
into secretory pattern. 
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Figure 3.4.17- 3.4.20 Benign Neoplasms. 
Figure 3.4.17 Fibroma. The tumor composed entirely of collagenous connective 
tissues without any epithelial component. 
Figure 3.4.18 Fibroma. The figure showed a fibroma with fibroblastic 
proliferations. 
Figure 3.4.19 Adenoma. The tumor was composed entirely of glandular epithelial 
structures. Secretory material could be observed in the alveolar lumina and epithelial 
cytoplasm. 




Figure 3.4.21 - 3.4.26 carcinoma in situ 
Figure 3.4.21 & Figure 3.4.22 Papillary Ductal Carcinoma. The ductal structures 
were dilated and occupied by the epithelial papillae. 
Figure 3.4.23 & Figure 3.4.24 Papillary Ductal Carcinoma with Cystic Structures. 
Papillae lined by layers of cuboidal epithelial cells projected towards cystic cavity. 
The fibroconnective tissue in the papillary core was edematous. Figure 3.4.24 
showed the details of the papilla. The edematous core of the papilla was infiltrated 
by lymphocytes and contained cell detritus. 
Figure 3.4.25 Cribriform Ductal Carcinoma. Formation of secondary lumina was 
found in the intraductal epithelium proliferations. 
Figure 3.4.26 Comedo Ductal Carcinoma. The carcinoma appeared as a distended 




Figure 3.4.27 - 3.4.32 Comparison Between Tubular Carcinoma and Papillary 
Carcinoma. ‘ -
Figure 3.4.27 Tubular Carcinoma. There was a monotonous expense of closely 
packed tubular structures varying from round to elongated in shape. 
Figure 3.4.28 Papillary Carcinoma. The tumor consisted of multiple branching 
papillae covered by layers of cuboidal epithelial cells. 
Figure 3.4.29 Details of the Tubular Carcinoma. The lumina of the tubular 
carcinoma were usually narrow and empty. 
Figure 3.4.30 Higher Magnification of Papillae in Papillary Carcinoma. The 
papillae were covered by cuboidal epithelial cells. 
Figure 3.4.31 Tubular Carcinoma. The lumina of the tubular structures were 
generally empty and narrow. Occasionally, secretory material could be found. 




Figure 3.4.33 -3.4.38 Invasive Ductal Carcinoma. 
Figure 3.4.33 & Figure 3.4.34 Invasive Cribriform Carcinoma. Secondary lumina 
were observed in the carcinoma. 
Figure 3.4.35 & Figure 3.4.36 Invasive Comedo Carcinoma. 
Figure 3.4.37 & Figure 3.4.38 Invasive Papillary Carcinoma. 
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Figure 3.4.39 - 3.4.42 Carcinoma Invasion to Stromal Tissue. 
Figure 3.4.43 - 3.4.44 Carcinoma Invasion to Adjacent Skeletal Muscles. 
Figure3.4.45 - 3.4.46 Suspected Metastasis of Mammaiy Carcinoma to Lung. The 
alveolar lining of lung was obviously thickened. This might due to the deposit of the 
metastatic mammary carcinoma cells on the alveolar wall. 
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Figure 3.4.47 Invasion. The upper right comer of figure 3.4.47 showed a relatively 
well-differentiated region in a mammary carcinoma. In this area, the carcinoma cells 
retained the tendency to form the ductal or alveolar cystic structures. Figure A and B 
showed the details of these cystic structures. The lower left comer of figure 3.4.47 
showed a poorly-differentiated anaplastic carcinoma. Cluster of epithelial cells could 
be found in the stromal tissues. Figure C and D showed the details of these 
infiltrating carcinoma cells. 
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Figure 3.4.48 - 3.4.53 Histopathological Heterogeneity of Spontaneously Developed 
Mammary Tumor. 
Figure 3.4.48 There was a progressive increase of fibroblastic proliferation in this 
sample of fibroma. The upper left comer of the tumor was composed entirely of 
collagenous connective tissue. In the lower right comer, bundles of fibroblasts were 
observed. 
Figure 3.4.49 The upper left comer of the figure showed a fibroma. However, on 
the lower left comer, the histopathology of tumor shifted arbitrarily into a secretory 
fibromadenoma. On the lower right comer, a non-secretory fibroadenoma was 
observed. 
Figure 3.4.50 A focal secretory area was observed in the tubular carcinoma. 
Figure 3.4.51 The pathology of the tumor progressively changed from an adenoma 
(upper region) into a comedo carcinoma (lower region). 
Figure 3.4.52 A comedo ductal carcinoma was found in a fibroadenoma. 
Figure 3.4.53 An adenoma (upper left comer) was found within a papillary 
carcinoma (lower right comer). 
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Figure 3.4.54 & 3.4.55 Early Histological Changes in Hormone-Treated Mammary 
Glands. There was extensive formation of the enlarged cystic lobules. The histology 
of Individual alveolus of the lobule was relatively normal. Stroma surrounding the 
cystic alveoli was composed of normal adipose cells 
Figure 3.4.56 & 3.4.57 Details of Individual Alveoli in Hormone-Induced Cystic 
Lobules. The histology of alveoli was relatively normal. The white arrow in figure 
-3.4.56 indicated that the alveolar epithelium was cuboidal in shape and was one layer 
thick. The black arrow in figure 3.4.56 indicated an early atypical epithelial 
hyperplasia observed in adjacent alveolus. Figure 3.4.57 indicated another example 
of the atypical epithelial hyperplasia. The contour of the alveoli was irregular. The 
lining epithelium was more than one layer thick. 
Figure 3.4.58 Hormone-Induced Mammary Carcinoma, Cribriform Pattern. 
Figure 3.4.59 Hormone-Induced Mammary Carcinoma, Mixed Cribriform and 
Comedo Pattern. 
Figure 3.4.60 Hormone-Induced Mammary Carcinoma. Clusters of neoplastic 
epithelial cells were found in the distended cystic lumen. 
Figure 3.4.61 Hormone-Induced Mammary Carcinoma. The core region of the 
detached carcinoma islets was composed of edematous fibroconnective tissues. 





Figure 3.4.62 - 3.4.65 DMBA-induced Mammary Carcinoma in Female Noble Rats 
Figure 3.4.62 Invasive Ductal Carcinoma, Cribriform Pattern. 
Figure 3.4.63 Invasive Ductal Carcinoma, Comedo Pattern. 
Figure 3.4.64 Invasive Ductal Carcinoma, Papillary Pattern. 
- Figure 3.4.65 Anaplastic Carcinoma. Lines of epithelial cells were invading 
surrounding stromal tissues. 
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Figure 3.5.1 - 3.5.3 Whole Mount Preparation of Noble Rat Mammary Gland. 
Figure 3.5.1 Intact Virgin Noble Rat Mammary Gland. The gland contained 
numerous sparsely distributed, club-shaped lateral alveolar buds and terminal end 
buds. 
Figure 3.5.2 Virgin Noble Rat Mammary Gland After 10-day T+E2 Treatment. 
After short-term hormonal treatment, the cystic alveolar buds increased in number 
and size. The terminal ducts were also thickened. Terminal buds were not found at 
the ending of the terminal duct. 
Figure 3.5.3 Virgin Noble Rat Mammary Gland After 2-month T+E2 Treatment. 
Prolonged hormonal treatment resulted in further increase in the number and size of 
the cystic alveolar buds. 
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Figure 3.7.1 Spontaneously Developed Benign Secretory Adenoma From a 14 
Months Old Female Noble Rat. The alveolar Lumina were dilated and contained 
plenty of secretory materials. Only scanty connective tissue was present. 
Figure 3.7.2 Spontaneously Developed Benign Secretory Fibroadenoma From a 12 
Months Old Female Noble Rat. The secretory tubular alveolar components were 
separated by septa of connective tissue. 
Figure 3.7.3 Spontaneously Developed Benign Nonsecretory Fibroadenoma From 
a 13 Months Old Female Noble Rat. Concentric layers of dense connective tissue 
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Figure 3.8.1 - 3.8.8 Immunohistochemical Analysis of Epithelial Keratin Expression 
In Spontaneously Developed Mammary Tumors . 
Figure 3.8.1 Normal Female Noble Rat Mammary Gland. The cytoplasm of the 
normal mammary epithelial cells was positively stained for keratins. 
Figure 3.8.2 Spontaneously Developed Benign Fibroadenoma. The cytoplasm of the 
alveolar epithelial cells was strongly positively stained with keratin. 
Figure 3.8.3 & 3.8.4 Spontaneously Developed Carcinoma In Situ. The papillary 
tumor cells were well circumscribed by stromal tissues. The cytoplasm of individual 
epithelial cells was positively stained with keratin. 
Figure 3.8.5 & 3.8.6 Invasive Ductal Carcinoma. Clusters of epithelial cells were 
invading surrounding stromal tissue. The cytoplasm of the carcinoma cells was 
heavily stained with keratins. 
Figure 3.8.7 Anaplasic Carcinoma. As a result of the invasion, islets of positively 
stained epithelial cells could be found in the stromal cells. 
Figure 3.8.8 Invasion of Anaplastic Carcinoma. Individual positively stained 
anaplastic carcinoma cells were invading surrounding normal mammary stromal 
tissues. 
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Figure 3.9.1 - 3.9.2 Negative Control for Immunohistochemsitry. Primary Antibody 
was omitted to examine the specificity of the immunohistochemical signals. 
Immunoreactivity was not observed in the negative control samples. 
Figure 3.9.1 Female Noble Rat Uterus. 
Figure 3.9.2 Female Noble Rat Mammary Gland. 
Figure 3.9.3 - 3.9,8 Expression and Localization of Hormone Receptors in Control 
Tissue. 
Figure 3.9.3 & 3.9.4 Immunohistochemistry of Estrogen Receptor a in Adult Noble 
Rat Uterus. Strong nuclear staining was observed in most endometrial and stromal 
cells 
Figure 3.9.5 & 3.9.6 Immunohistochemistry of Estrogen Receptor |3 in Adult Noble 
Rat Uterus. Strong nuclear staining was observed in most endometrial cells, stromal 
cells and skeletal muscle cells. 
Figure 3.9.7 & 3.9.8 Immunohistochemistry of Progesterone Receptor in Adult 






Figure 3.9.21 - 3.9.14 Immunohistochemical Analysis of Expression and 
Localization of Progesterone Receptor in Mammary Glands and Tumors of Noble 
Rats. 
Figure 3.9.9 Normal Female Noble Mammary Gland. Intense nuclear 
immunostaining was observed in the normal mammary epithelial cells. 
Figure 3.9.10 Spontaneously Developed Benign Tumor. Strong nuclear 
immunostaining was observed in the alveolar epithelial tumor cells. 
Figure 3.9.11 Spontaneously Developed Malignant Carcinoma. The nuclei of 
carcinoma cells were heavily positively stained. 
Figure 3.9.12 DMBA-Induced Malignant Carcinoma. Moderate immunoreactivity 
was observed in both carcinoma and stromal cells. 
Figure 3.9.13 T+Ea-Induced Malignant Carcinoma. The nuclei of the carcinoma cells 
were strongly stained. 
Figure 3.9.14 T+DES-Induced Malignant Carcinoma. The cytoplasm and nuclei of 
the carcinoma cells were strongly stained. 
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Figure 3.9.21 - 3.9.20 Immunohistochemical Analysis of Expression and 
Localization of Progesterone Receptor in Mammary Glands and Tumors of Noble 
Rats. 
Figure 3.9.15 Normal Female Noble Mammary Gland. Moderate cytoplasmic and 
nuclear staining was observed in the ductal epithelial cells. 
Figure 3.9.16 Spontaneously Developed Benign Tumor. The cytoplasm of the benign 
tumor cells only exhibited weak to moderate staining. 
Figure 3.9.17 Spontaneously Developed Malignant Carcinoma. Moderate 
cytoplasmic staining was observed in the ductal carcinoma cells. 
Figure 3.9.18 DMBA-Induced Malignant Carcinoma. Only very low 
immunoreactivity was observed in the carcinoma cells 
Figure 3.9.19 T + Ez-Induced Malignant Carcinoma. The carcinoma cells exhibited 
very strong cytoplasmic staining. 
Figure 3.9.20 T+DES-Induced Malignant Carcinoma. Intense cytoplasmic 
immunoreactivity was observed in the carcinoma cells. 
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Figure 3.9.21 - 3.9.26 Immunohistochemical Analysis of Expression and 
Localization of Progesterone Receptor in Mammary Glands and Tumors of Noble 
Rats. 
Figure 3.9.21 Normal Female Noble Mammary Gland. Moderate nuclear 
immunostaining was observed in the normal mammary epithelial cells. 
Figure 3.9.22 Spontaneously Developed Benign Tumor. Strong nuclear 
immunostaining was observed in the alveolar epithelial tumor cells. 
Figure 3.9.23 Spontaneously Developed Malignant Carcinoma. The nuclei of 
carcinoma cells were heavily positively stained. 
Figure 3.9.24 DMBA-induced Malignant Carcinoma. Moderate immunoreactivity 
was observed in carcinoma cells. 
Figure 3.9.25 T+Ez-Induced Malignant Carcinoma. The nuclei of the carcinoma cells 
were moderately stained. 
Figure 3.9.26 T+DES-Induced Malignant Carcinoma. The nuclei of the carcinoma 
cells were strongly stained. 
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Figure 3.9.27 Negative Control for Immunohistochemsitry of Androgen Receptor. 
Primary Antibody was omitted to examine . the specificity of the 
. i 
immunohistochemical signals on rat prostate. Immunoreactivity was not observed in 
the negative control sample. 
Figure 3.9.28 Immunohistochemistry of Androgen Receptor in Adult Noble Rat i 
i 
Prostate. Strong nuclear and cytoplasmic immunoreactivity were observed in the 
glandular epithelium. 
Figure 3.9.29 Negative Control for Immunohistochemsitry of Prolactin Receptor in 
Lactating Mammary Glands. Immunoreactivity was not detected in the negative 
control sample. 
Figure 3.9.30 Immunohistochemistry of Prolactin Receptor in Lactating Noble Rat 
Mammary Gland. Strong immunoreactivity was observed in the cell membranes of 
the alveolar epitheliums. 
Figure 3.9.31 Negative Control for Immunohistochemsitry of Prolactin Receptor in 
Rat Liver. Immunoreactivity was not detected in the negative control sample. 
Figure 3.9.32 Immunohistochemistry of Prolactin Receptor in Female Noble Rat 
Liver. Strong immunoreactivity was observed in the cell membranes and 




Figure 3.9.21 - 3.9.33 Immunohistochemical Analysis of Expression and 
Localization of Progesterone Receptor in Mammary Glands and Tumors of Noble 
Rats. 
Figure 3.9.33 Normal Female Noble Mammary Gland. Only moderate 
immunoreactivity was observed in the epithelial cells. 
Figure 3.9.34 Spontaneously Developed Benign Tumor. Strong nuclear and 
cytoplasmic immunoreactivity was observed in the alveolar epithelial tumor cells. 
Figure 3.9.35 Spontaneously Developed Malignant Carcinoma. The nuclei of the 
carcinoma cells were heavily stained. 
Figure 3.9.36 DMBA-Induced Malignant Carcinoma. Moderate immunoreactivity 
was observed in the carcinoma cells. 
Figure 3.9.37 T+E2-Induced Malignant Carcinoma. The nuclei of the carcinoma cells 
were moderately stained for AR. 
Figure 3.9.38 T+DES-Induced Malignant Carcinoma. The nuclei and cytoplasm of 
the carcinoma cells were strongly stained for AR 
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Figure 3.9.21 - 3.9.96 Immunohistochemical Analysis of Expression and 
Localization of Progesterone Receptor in Mammary Glands and Tumors of Noble 
Rats. 
Figure 3.9.39 Normal Female Noble Mammary Gland. Weak to moderate 
cytoplamic immunoreactivity was observed in the normal mammary epithelial cells. 
Figure 3.9.40 Spontaneously Developed Benign Tumor. Strong immunoreactivity 
was observed in the plasma membranes and cytoplasm of most epithelial tumor cells. 
Figure 3.9.41 Spontaneously Developed Malignant Carcinoma. The plasma 
membrane and cytoplasm of carcinoma cells were heavily stained for PRLR. 
Figure 3.9.42 DMBA-Induced Malignant Carcinoma. Strong PRLR 
immunoreactivity was observed in focal areas. — 
Figure 3.9.43 T+Ez-Induced Malignant Carcinoma. The cytoplasm of the carcinoma 
cells was weakly to moderately stained for PRLR. 
Figure 3.9.44 T+DES-Induced Malignant Carcinoma. The cytoplasm and plasma 
membrane of the carcinoma cells were strongly stained. 
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Figure 3.10.1 Western Blot Analysis of Expression of Estrogen Receptor a 
Proteins in Normal and Neoplastic Mammary Tissues of Female Noble Rats 
O g « 2 2 a E E 93 es B B 5 « C8 o o c c o o O 2 g s e c g g c c: 
s ^ o o -S -S c c -S ^ flee 二 二 .is 二 
W) T! « « H y r®^  r®* «« 
Z. G ^ ^ ^ o « « ^ ^ g 
03 ^ CQ CQ ^ ^ JZi 





84KD— • ^ Native ER 
. . ： ^ : ’ ， • 一 — — “ 4 6 7 K D 
Putative ER 
52.2KD— — 如 KD 
21.9KD— • 
7.5KD — —— 
Figure 3.10.2 Western Blot Analysis of Expression of Estrogen Receptor p 
Proteins in Normal and Neoplastic Mammary Tissues of Female Noble Rats 
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Table 3.1. Incidence rate, Distribution and Histopathology of the Spontaneously 
Developed Mammary Tumors in Female and Male Noble Rats 
Nb rat Age Mammary tumor location Histopathology  
1. Female 8 months old Left thoracic gland Benign Fibroma 
2. Female 12 months old Left abdominal gland Benign fibroadenoma 
3. Female 12 months old Right thoracic gland Benign Fibroadenoma 
Left thoracic gland Benign Fibroadenoma 
4. Female 13 months old Right abdominal gland Malignant invasive ductal carcinoma 
5. Female 13 months old Right upper thoracic mammary gland Benign Fibroadenoma 
Right lower thoracic mammary gland Benign Fibroadenoma 
6. Female 14 months old Right thoracic mammary gland Benign Fibroadenoma 
7. Female 14 months old Right thoracic mammary gland Benign adenoma 
Left thoracic mammary gland Benign Fibroadenoma 
8. Female 14 months old Left thoracic mammary gland Benign Fibroadenoma 
9. Female 14 months old Left thoracic mammary gland Benign Fibroadenoma 
10. Female 14 months old Right inguinal mammary gland Malignant papillary adenocarcinoma 
11. Female 14.5 months old Left abdominal mammary gland Malignant papillary 
Adenocarcinoma 
12. Female 15 months old Right upper thoracic mammary gland Benign Fibroadenoma 
Right lower thoracic mammary gland Benign Fibroadenoma 
Right abdominal mammary gland Benign Fibroadenoma 
Right inguinal mammary gland Benign Fibroadenoma 
13. Female 15 months old Right thoracic mammary gland Benign Fibroma 
14. Female 15 months old Left thoracic mammary gland Benign Fibroadenoma 
15. Female 15 months old Left abdominal mammary gland Benign Fibroadenoma 
- 16. Female 16 months old Right thoracic mammary gland Benign Fibroadenoma 
Left thoracic mammary gland Benign Fibroadenoma 
Right inguinal mammary gland Benign Fibroadenoma 
17. Female 18 months old Left thoracic mammary gland Malignant papillary adenocarcinoma 
18. Female 18 months old Left inguinal mammary gland Malignant tubular adenocarcinoma 
19. Male 12 months old Right abdominal mammary gland Benign Fibroadenoma 
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Table 3.2. Incidence Rate, Latency Period and Distribution of Mammary Tumors in 
Female Noble Rats Under Combined Treatment of Testosterone and 17p-Estradiol 
Treatment Age Latency Mammary lesion locations Other Observations 
T+E2 Period  
1. 11 months old 8 months Right upper thoracic gland: fluid lesion i. Ovary and uterus 
Right lower thoracic gland: solid tumor appeared abnormal 
Right abdominal gland: fluid lesion 
Left thoracic gland: fluid lesion 
Left abdominal gland: fluid lesion 
2. 11 months old 8 months Right abdominal gland: fluid lesion i. The rat was moribund 
Left thoracic gland: fluid lesion 
Left abdominal gland: fluid lesion 
3. 11 months old 8 months Right thoracic gland: fluid lesion i. Uterine tumor was 
Right abdominal gland: fluid lesion found “ 
Left thoracic gland: fluid lesion 
Left abdominal gland: fluid lesion 
4. 11 months old 8 months Left upper thoracic gland: fluid lesion Nil 
Left lower thoracic gland: fluid lesion 
Left abdominal gland: fluid lesion 
5. 13 months old 9 months Right thoracic gland: fluid lesion Nil 
Right upper abdominal gland: fluid lesion 
Right lower abdominal gland: solid tumor 
Left thoracic gland: fluid lesion 
Left upper abdominal gland: fluid lesion 
Left lower abdominal gland: solid tumor 
6. 13 months old 10 months Right cervical gland: fluid lesion Nil 
Right thoracic gland: fluid lesion 
Right abdominal gland: fluid lesion 
Left thoracic gland: fluid lesion 
Left abdominal gland: fluid lesion 
7. 15 months old 11 months Right thoracic gland: fluid lesion i. The rat was moribund 
Right inguinal gland: fluid lesion ii. Uterus and ovary 
appeared abnormal 
iii. Lung also appeared 
abnormal 
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Table 3.3. Latency Period and Distribution of Mammary Tumors in Female Noble 
Rats under Combined treatment of Testosterone and Diethylstilbestrol 
Treatment Age Latency Mammary lesion locations Other Observations 
T+DES Period  
1. 12 months old 9 months Right upper thoracic gland: fluid lesion i. The rat was moribund 
Right abdominal gland: fluid lesion ii. Uterus appeared 
Left thoracic gland: solid tumor abnormal 
Left abdominal gland: fluid lesion iii. Lung also appeared 
abnormal 
2. 13 months'old 10 months Right abdominal gland: solid tumor i. The rat was moribund 
Left cervical gland: solid tumor ii. Uterus and ovary 
Left thoracic gland: fluid lesion appeared abnormal 
Left abdominal gland: fluid lesion iii. Lung and liver also 
appeared abnormal 
3. 13 months old 10 months Left thoracic gland: solid tumor i. Uterus and ovary 
appeared abnormal 
4. 13 months old 10 months Right cervical gland: solid tumor i. The rat was moribund 
Right thoracic gland: solid tumor ii. Uterus and ovary 
Left abdominal gland: fluid lesion appeared abnormal 
iii. Lung and liver also 
appeared abnormal 
5. 14 months old 11 months Right abdominal gland: fluid lesion i. Uterus and ovary 
Left thoracic gland: fluid lesion appeared abnormal 
Left abdominal gland: solid tumor 
Table 3.4. Incidence Rate And Latency Period of the Hormone Induced Mammary 
Tumors in Female Noble Rats 
Treatment Number of Female Noble Rats Mortality Incidence Rate Average Latency Period _ 
under Hormonal Treatment  
f+E^ 20 5/20 25% 7/15 46.66% 8.86 months 
T+DES M 11/20 55% 5/9 55.55% 10 months  
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Table 3.5. Changes in Volume of the Spontaneously Developed Mammary Tumors in 
the Bilateral Ovariectomized Noble Rats 
Bilateral Ovariectomized Noble Rat 
Weeks after 1 I 2 I 3 ~ 
Operation L e n g t h W i d t h H e i g h t Tumor Length Width Height Tumor Length~WidthHeight Tumor 
(mm) (mm) (mm) Volume (mm) (mm) (mm) Volume (mm) (nun) (mm) Volume  
(— (mm^ ) (mm】） 
0 28.12 25.81 17.22 6.25 20.33 24.59 5.09 1.27 29.79 28.62 18 7.67 
1 28.12 25.81 17.19 6.24 20.35 24.53 5.04 1.26 29.64 28.59 17.91 7.59 
2 28.65 26.12 17.16 6.42 19.18 24.76 5.42 1.29 31.72 32.38 17.1 8.78 
3 28.45 27.13 16.93 6.53 19.71 25.67 5.31 1.34 33.86 31.04 18.9 9.93 
4 29.73 26.34 17.76 6.95 18.89 25.78 4.75 1.16 34.85 30.05 18.9 9.90 
5 29.1 25.63 18.65 6.95 19.87 29.24 7.28 2.11 34.99 31.72 19.23 10.67 
6 29.21 26.88 18.11 7.11 20.27 30.99 8.59 2.70 35.73 32.64 20.54 11.98 
7 29.49 26.86 19 7.52 21.31 30.87 8.69 2.86 36.64 32.24 21.63 12.78 
8 29.14 27.91 19.32 7.86 21.78 32.21 10.97 3.85 37.33 34.54 21.79 14.05 
Table 3.6. Details of the Transplanted Spontaneously Developed Mammary Tumors 
collected from Female or Male Noble rats. 
Noble Sex Age Tumor Location Tumor Gross Histopathology 
Rat appearance  
1 Female 14 Right thoracic White and Benign secretory adenomna; 
months mammary gland rubbery lump Lactating alveoli with scanty 
old with plenty milk connective tissues. 
secretion (Figure 3.3.1) 
2 Female 12 Right thoracic White, rubbery, Benign secretory fibroadenoma; 
months mammary gland lump with milk Mixed stromal and epithelial pattern 
old secretion (Figure 3.3.2) 
3 Male 13 Right abdominal White, rubbery Benign nonsecretory fibroadenoma; 
months mammary gland firm lump Concentric layers of connective tissue 
old with few ductules 
(Figure 3.3.3) 
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Table 3.7 Immunohistochemical Analysis of Hormone Receptors in Normal and 
Neoplastic Mammary Tissues in Female Noble Rats 
Relative Immunoreactivity Intensity * 
Estrogen Estrogen Progesterone Androgen Prolactin  
Receptor a Receptor (3 Receptor Receptor Receptor 
Normal Mammary Gland +++ ++ + + + + + + + 
Spontaneously Developed: 
Benign Tumor + + + + + + + + + + + + + + 
Malignant Carcinoma +++ ++ -hhh +++ ++ 
DMBA Induced Carcinoma ++ - / + ++ ++ +++ 
T+E2 Induced Carcinoma +++ -H-f ++ -hh- ++ 
T+DES Induced Carcinoma + + + + + + + + + -hh- -hh-
Immunoreactivity intensity in arbitrary scales: +++ Strongly Positive 
++ Moderately Positive 
+ Weakly Positive 
- Negative 
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Chapter 4. Discussions 
4.1 Comparison of the Incidence Rate of Spontaneously developed 
Mammary Tumors in Noble Rats with the Previously Reported Incidence Rate 
In the present study, the incidence rate of spontaneous mammary tumors in 
Noble rats was found to be 45 % in the females and 3.13 % in the males. On the 
other hand, the incidence rate of the spontaneous mammary tumors in the aged 
Noble rats as reported by Dr RL Noble in two decades ago was 25 % in the females 
and 2 % in the males (Noble et al, 1975). In comparison, the incidence rate of 
spontaneous tumor in the male Noble rats of the present colony is higher than, but is 
still very close to, the reported figure. However, the incidence rate of the 
spontaneous mammary tumors in our colony of female Noble rats is much higher 
than the reported figure, it is nearly double the one reported by Dr RL Noble (Noble 
et al, 1975). Nevertheless, it is not uncommon that different incidence rates of 
spontaneous mammary tumors are reported in the same rat strain by different and 
even the same laboratories. For example, variability of incidence rates of 
spontaneous mammary tumors is also reported in the most commonly used rat 
strains, including the Sprague-Dawley (SD) and Wistar rats (Sher, 1972; Manik et 
al, 1992; Kathleen & James，1994). In the female SD rats, spontaneous tumor 
incidences of 55 %�62 %, 64 % and even as high as 85 % were reported (Sher, 
1972). The reported tumor incidences in male SD rats also range from 19 % to 44 % 
(Sher, 1972). The exact reasons for these variations are difficult to explain as a lot of 
factors can affect the spontaneous tumor incidence during the study. These include 
the difference in the habitat environments such as the dietary contents, the temporal 
length of dark/light cycle, background radiations and other factors such as the 
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presence of carcinogens or virus, the length of study, the age and mortality of the 
animals, the sample numbers, the germline mutations of the rat colony (Noble & 
Cutts, 1959; Sher, 1972). However, the involvement of vims can be excluded in this 
case. As females are more susceptible to the development of breast cancers, the 
effects of these possible factors are believed to be more significant in the females as 
compared with the males. All these possible factors may contribute to our present 
observation that there is great derivation of incidence rate of spontaneous mammary 
tumors in the female Noble rats but not in the males. 
4.2 Comparison of the Incidence rate of Spontaneously Developed Mammary 
Tumors in Noble Rats with the Incidence Rate in Other Rat Strains 
The incidence rate of spontaneous mammary tumors developed in Noble rats 
in the present study is 45 % in the females and 3.13 % in the males. These incidence 
rates are compared with the previously reported data in other extensively used rat 
strains. It is found that in many aged female rat strains, the spontaneous mammary 
tumors also occur with a frequency up to 45%. These include the Wistar (Sher, 1972; 
Walsh and Poteracki, 1994), F344 (Chandra & Frith, 1992), SD (Sher, 1972) and the 
Osbome-Mendel strains (Sher, 1972). On the other hand, the incidence rate of 
spontaneous mammary tumors in the male Noble rats is also similar to the previously 
reported data in the other rat strains, including the SD, F344 and Wistar strains 
(Sher, 1972; Noble et al, 1975; Chandra et al, 1992; Walsh & Poteracki, 1994). 
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4.3 Crucial Factors Influencing the Incidence Rate of Spontaneously 
Developed Mammary Tumors in Noble Rats 
It is observed that the spontaneous mammary tumors develop much more 
commonly in the aged populations, normally when the Noble rats are over 1 year 
old. It is also observed that the female rats are much more susceptible to develop 
spontaneous mammary tumors as compared with the males. These observations are 
consistent with the previously reported data in the other rat strains, including the SD, 
-F344 and Wistar strains (Noble & Cutts，1959; Sher, 1972; Noble et al, 1975; 
Chandra et al, 1992; Walsh— & Poteracki，1994). The high incidence of 
spontaneously developed mammary tumors in the aged female population is possibly 
due to the lifetime accumulations of carcinogenic mutations in the aged animals and 
the high systemic estrogen levels in the female animals. Current views on the 
oncogenetic basis of female breast cancer suggest that the malignant transformation 
of the normal breast epithelium into an invasive carcinoma is a multistep process, in 
which a number of genetic alternations have occurred within various critical genes, 
that are directly or indirectly responsible for regulating certain important cellular 
processes, such as cell proliferation, differentiation, chromosomal replication and 
apoptosis (Lakhani, 1999). As temporal accumulations of these sporadic 
carcinogenic mutations are a prerequisite for the development of a tumor, breast 
cancer is thus more commonly found in the aged populations. On the other hand, the 
most well-documented risk factors of breast cancer, such as early menarche, late 
menopause and nulliparity, are associated with the most significant physiological 
changes in the estrogen secretion during a female's lifetime. These clinical 
observations strongly suggest that estrogen plays a crucial role in the development of 
human breast cancer (McPherson et al, 2000). Therefore, the higher incidence of the 
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mammary tumors in the females is believed correlated to the higher endogenous 
secretions of estrogen. The possible mechanisms that estrogen acts as endogenous 
carcinogens in breast cancer will be discussed in the following sections. 
4.4 Comparison of the T+E2 Induced Mammary Tumors with the T+DES 
Induced Mammary Tumors in Female Noble Rats 
In the hormone-induced mammary tumors of female Noble rats, the 
incidence rate in the testosterone and diethylstilbestrol (T+DES) treatment (55.55 %) 
_ is higher than that in the testosterone and 17p-estradiol (T+E2) treatments (46.66 %). 
On the other hand, the average latency period of the T+ DES-induced mammary 
tumors (10 months) is also longer than that of the T+Ez-induced mammary tumors 
(8.86 months). Furthermore, the mortality of the T+DES-treated rats (55 %) is much 
higher than that of the T+E2-treated group (25 %). These differences between the 
T+DES and T+E2 treatments are probably due to the derivations in the estrogenic 
activity and carcinogenicity between the synthetic estrogen, DES, and the 
I 
physiological occurring estrogen, 17p-estradiol. Both the DES and E2 can bind to the 
estrogen receptors (ER) (Korach et al, 1991). However, DES has a higher affinity 
for receptor binding as compared with E2. As a result, DES leads to longer duration 
of ER activation and higher estrogenic activity in the affected animals (Marselos & 
Tomatis, 1992; 1992b). On the other hands, the biological effects of these estrogenic 
compounds on the mammary gland may also result indirectly from their metabolic 
activation to reactive metabolites (Russo et al, 2001). The resulted systemically 
active metabolites may possess different biological activities and finally lead to the 
disparate behaviors between the T+DES and T+ E2-induced mammary tumors. 
Previous studies had already shown that both the DES and E2 were able to induce 
105 
lobuloalveolar hyperplasia or mammary tumor in Noble rats (Colerangle & Roy， 
1995; Liao et al., 1998; Odum et ai, 1999; Xie et al” 1999) or in other rat strains 
such as the ACI rats (Dunning et al., 1949; Schull et al, 1997; Harvell et al, 1999). 
In the present study, it is found that DES is able to provide higher incidence rate of 
induced-mammary tumors in female Noble rats as compared with E2. However, 
higher frequency of mortality and abnormality in the reproductive organs, such as 
ovary and uterus, is also resulted in the T+DES-treated animals. It has already been 
established that DES is a carcinogen and its carcinogenicity has been demonstrated 
in rats, mice, hamsters, dogs, monkeys and even human (Marselos & Tomatis，1992; 
1992b). The target organs of DES include the vagina, cervix, uterus, ovary, and the 
mammary gland (Marselos & Tomatis，1992; 1992b). Hence, the high death rate and 
the frequent abnormalities induced in ovaiy and uterus observed in the T+DES-
treated Noble rats may be due to the strong carcinogenicity of DES. 
4.5 Comparison of the Incidence Rate & Latency Period of the Hormone 
Induced Mammary Tumors in Noble Rats with the Previously Reported Data 
In a previous study by Dr YC Wong and colleagues, it was reported that a 
combined treatment of androgen (testosterone propionate) and estrogen (17p-
estradiol benzoate) could induce a high incidence of mammary tumors in female 
Noble rats within relatively short time (Xie et al” 1999). The incidence rate of the 
induced-mammary tumors was 52.78 %，with average tumor latency period of 5.82 
months. In our study, the incidence rate of the T+E2 induced mammary tumor is 
46.66 % and the tumor latency period is 8.86 months. In comparison, the incidence 
rate of the T+E2-induced mammary tumors under the present study (46.66 %) is 
lower than, but is still similar to, the figure reported by Dr. YC Wong (52.78 %). 
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However, the tumor latency period of the present study (8.86 months) is much longer 
than the reported latency period (5.82 months). These differences may be due to the 
variations in the dosage of testosterone administered. In the present study, only two 
2_cm testosterone tubings were implanted subcutaneously into the female Noble rats, 
as compared with four 2-cni testosterone tubings in Dr YC Wong's study. These 
observations suggest that the role of androgen in this hormone-induced model of 
female Noble rats is to speed up the estrogen-induced mammary carcinogensis. This 
result is consistent to the hypothesis proposed by Dr YC Wong (Xie et al, 1999b). 
4.6 Comparison of the Phenotypic Behaviors in Spontaneously Developed 
Mammary Tumors with the Hormone Induced Mammary Tumors in Female 
Noble Rats 
In comparison, the incidence rate of the spontaneously developed mammary 
tumors (45 %) is similar to that of the T+Ez-induced tumors (46.66 %). However, the . 
latency period of the hormone-induced tumors is much shorter than that of the 
spontaneously occurring neoplasms. The average age of the female Noble rats for the 
occurrence of spontaneous mammary tumor is about 14 months old. However, the 
average age of the female Noble rat for the incidence of hormone-induced mammary 
tumors is much lower and is only 10 months old. These observations suggest that the 
hormonal treatment is able to speed up the carcinogenesis without altering the final 
tumor incidence. 
It has been repeatedly shown that estrogen is a mitogen and is able to 
stimulate cell cycle progression in the normal mammary epithelium and the ERa 
expressing cancer cells, thereby resulting in the proliferation of the normal and 
neoplastic mammary tissues (Foidart et al, 1998; Zhou et al, 2000). The high 
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incidence rate of the spontaneously developed mammary tumors in female Noble rat 
suggests that sporadic oncogene mutations may occur frequently in this rat colony. 
Sporadic oncogene mutations are not uncommon in rat strains. It was previously 
reported that spontaneous oncogenic GGA to GAA mutations in the 12th codon of 
the Hras gene are frequently detected during the normal development of the 
mammary epithelium of female F344 rats (Cha et al, 1994). On the other hand, it is 
now clear that proliferating mammary cells are prerequisites for the breast 
carcinogenesis (Nandi et al, 1995). Therefore, estrogen may contribute to the 
initiation of the mammary gland carcinogenesis by increasing the rate of cell 
proliferation in the breast epithelium, thereby enhancing the occurrence of oncogenic 
mutation in the mammary glands. The whole mount preparation of the hormone-
treated mammary glands have demonstrated that sex steroids are potent mitogen in 
the mammary glands of female Noble rats as extensive lobuloalveolar proliferation 
and differentiation are observed only ten days post the hormonal treatment. Besides, -
it is also suggested that estrogen can initiate mammary gland carcinogenesis directly 
by metabolic activation to form DNA adducts. The resulting mutations may leads to 
the development of breast tumors (Cavalieri et al, 1997; Liehr, 1997). 
A comparison between the histopathology of the spontaneously developed 
mammary tumors and the hormone-induced mammary tumors reveals that the 
hormone-induced tumors are much more malignant than the spontaneous tumors. 
Most of the mammary tumors develop spontaneously are benign fibroadenomas 
whereas those induced by hormones are poorly differentiated carcinomas. On the 
other hand, it is known that the mammary gland carcinogensis is a multistage 
process (Lakhani, 1999). The transition of the mammary gland from normal 
epithelium to invasive carcinoma involves a lot of intermediate pathological stages 
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such as non-atypical hyperplasia, atypical hyperplasia and in situ carcinoma. Based 
on our observations and the information from the literatures, it is hypothesized that 
the role of estrogen in the hormone-induced model of female Noble rats is to initiate 
the neoplastic transformation in the mammary gland. On the other hand, androgen 
may act as a promoter to speed up the development of the breast tumors. As more 
malignant carcinoma is observed in the hormone-induced model as compared with 
the spontaneously developed model, it is supposed that the promotion effect of 
_ androgen, alone or with estrogen, in the carcinogenesis is mainly on the malignant 
transformation of the benign tumors. 
4.7 Comparison of the Behaviors of Carcinogen Induced Mammary Tumors 
with Spontaneously Developed & Hormone Induced Mammary Tumors in 
Female Noble Rats 
The incidence rate of the carcinogen-induced mammary tumors (80 %) is 
much higher than that of the spontaneously developed (45 %) and hormone-induced 
mammary tumors (T+DES: 55.55 %; T+E2： 46.66 %) in female Noble rats. The 
mean latency period for the development of the carcinogen-induced mammary tumor 
is also much shorter (6.38 months) than that of the spontaneously occurring and the 
hormone-induced neoplasms. These disparate observations may suggest that the 
spontaneously developed and hormone-induced mammary tumors arise through a 
different carcinogenic mechanism as compared with the carcinogen-induced 
neoplasms in female Noble rats. This interpretation is further supported by the 
observations that the hormone receptor expression patterns in the carcinogen-
induced mammary tumors are different from that of the spontaneously developed 
and hormone-induced mammary tumors (to be discussed later). Pieces of evidence 
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can also be obtained from the literatures. It is well established that the biological 
effects of the steroid hormone, testosterone and 17p-estradiol, are mainly mediated 
by binding with specific cytoplasmic receptors. The activated hormone-receptor 
complex then migrates to the nucleus, complements to the hormone-responsive 
genes and finally modulates transcription of the target genes (Russo et al, 1999; 
Hansen & Bissell，2000). In the hormone-induced models, a prolonged and 
continuous supply of the exogenous hormone results in a consistent activation of the 
hormone receptors. The subsequent unregulated transcriptions of the corresponding 
hormone responsive genes are believed related to the mammary gland 
carcinogenicity. This may provide the basis of the hormone-induced carcinogensis in 
female Noble rats. For the spontaneously developed models, the sporadic mutations 
may result in unbalanced secretions of the steroid hormones or an unregulated 
activity of the hormone receptors. The unregulated transcriptions of the 
corresponding hormone responsive genes then induce the development of mammary 
tumors. Therefore, it is hypothesized that both the hormone-induced and 
spontaneously developed mammary tumors arise through a similar carcinogenic 
mechanism. On the other hand, although the chemical structure of DMBA is very 
similar to the estradiol, this chemical requires metabolic activation for its mammary 
gland carcinogenicity (Clarke, 1997). Liver and mammary glands are the important 
sites for the activation of DMBA, The ultimate carcinogenic DMBA metabolites are 
systemically active. It can bind to specific genes in the breast and leads to the 
development of mammary tumors (Singletary, 1990). The target genes for the 
DMBA may be in different loci as compared with the hormone responsive genes and 
this may leads to the derivations in the carcinogenic mechanisms in the mammary 
glands. Due to this discrepancy, the incidence rate, latency period and behaviors of 
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the carcinogen-induced mammary tumors are different from that of the hormone-
induced and spontaneously developed mammary tumors. 
4.8 Comparison of Expression Patterns of Hormone Receptor Proteins in 
Spontaneously Developed, Hormone Induced & Carcinogen Induced Mammary 
Tumors in Female Noble Rats 
The expression patterns of hormone receptors as detected by 
immunohistochemistry in the normal and neoplastic mammary tissue are 
summarized in Table 3.7, in which the intensities of immunoreactivity are expressed 
in arbitrary values. It has been observed that the hormone receptor statues in the 
spontaneously developed benign and malignant mammary tumors are very similar to 
those in the T+E2 and T+DES-induced tumors. In both the spontaneously developed 
and the hormone-induced models, the mammary tumors exhibit moderate to strong 
expression of different hormone receptors, including both the steroid receptors 
(ERa, ERP, PR and AR) and the cytokine receptor (PRLR). In contrast, the 
carcinogen-induced neoplasms only exhibit moderate immunoreactivity for the 
steroid receptor (ERa, ERp, PR and AR). However, a very strong immunostaining 
for PRLR was detected in these mammary tumors. These observations demonstrate 
additional pieces of evidence supporting the notion that the process of mammary 
gland carcinogenesis in the carcinogen-induced model may be different from that of 
the spontaneously developed and hormone-induced models in female Noble rats. As 
mutations of different oncogenes and tumor suppressor genes are involved during the 
mammary gland carcinogenesis in these different animal models, the conversion of 
the varied genetic information into a defined phenotype may lead to a discrepancy in 
the hormone receptor status between the carcinogen-induced mammary tumors and 
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the spontaneously developed as well as the hormone-induced neoplasms. The 
expression of individual hormone receptor in the spontaneously develop, hormone-
induced and carcinogen-induced mammary tumors in female Noble rats are further 
discussed as follows. 
4.9 Expressions of ERa & ERP Proteins in Spontaneously Developed, Hormone 
Induced and Carcinogen Induced Mammary Tumors in Female Noble Rats 
Moderate to strong nuclear ERa immunoreactivity - was detected in the 
spontaneously developed, hormone-induced and carcinogen-induced mammary -
tumors. On the other hand, the ductal and alveolar epithelial cells in the normal 
mammary glands also exhibited strong ERa nuclear expressions. These nuclear 
immunostaining for ERa suggests that the receptors have been activated by its 
ligand and is functionally active for modulation on ER-responsive gene 
transcriptions in both the normal and neoplastic mammary tissues. The uniform and 
intense expressions of the functionally active ERa clearly indicate an obligatory role 
for estrogen in the developments and functions of the normal mammary glands as 
well as the inductions and progressions of the mammary tumors in female Noble rats 
(Russo & Russo，1997). 
Native ERa is an approximately 67kDa protein identified in the rodent uterus 
(Jensen & Jacobson，1962; Horigome et al, 1987). Western blot analysis in previous 
studies has shown that ERa could exist in multiple isoforms (Geffroy-Roisne et al, 
1993； Faye et al, 1996). The existence of these ERa isoforms has been attributed to 
the proteolytic cleavage and phosphorylation of the receptor protein or possible 
association of the receptor with other carrier proteins. A recent study has shown that 
several ERa isoforms are involved in the hormone-induced mammary gland 
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carcinogenesis in male Noble rats (Liao et ai, 1998). In the present study, it was 
found that a 67kDa native protein was expressed in all form of mammary tumors. In 
comparison, it has been shown that the DMBA-induced neoplasms exhibited a 
weaker expression of this native 67kDa ERa protein. On the other hand, some of the 
DMBA-induced neoplastic samples also exhibit a weak expression of the putative 50 
kDa ERa isoforms. Moreover, the putative 50 and 54 kDa ERa isoforms were also 
detected in the spontaneously developed benign tumors and malignant carcinomas. 
Although the functional significances of these ERa isoforms are unknown, their 
presence suggests the possibility that the signaling mechanisms of ERa may vary 
between the models. A relatively intense ERa immunoreactivity as detected in the 
spontaneously developed and hormone-induced mammary tumors indicates that the 
developments of these tumors are relatively more dependent on estrogen, as 
compared with the carcinogen-induced mammary tumors in female Noble rats. 
Additional support for the greater estrogen dependency of the spontaneous and 
hormone-induced mammary tumors is demonstrated by the ERp status in these 
tumors. 
In the normal mammary glands of female Noble rats, a moderate ERp 
immunoreactivity was detected in most of the ductal and alveolar epithelial cells. 
Similar observation on ERP status was previously described in both human breasts 
and rodent mammary glands. ERp expression was detected in both normal and 
neoplastic human breast tissues (Warner et al” 2000). In rats, it was also reported 
that a large proportion of mammary epithelial cell expressed ERp proteins at all 
phrases of breast development and endocrine stimulations, including puberty, 
pregnancy and lactation (Saji et al. 2000). In the present study, expression of ERP 
proteins in the rat mammary tumors was found variable between different animal 
113 
models. Moderate to strong ERP expressions were detected in both spontaneously 
developed and hormone-induced mammary tumors. However, in the carcinogen-
induced breast tumors, only negative to weak ERp immunoreactivity was observed. 
Since the discovery of ERP from rat ovary and prostate in 1996 (Kuiper et al, 1996), 
the biological roles of ERp and its interaction with ERa in the mammary glands are 
still undefined. The positive expression of ERp in mammary tumors shows that this 
steroid receptor also plays a role in the mammary gland carcinogenesis. The intense 
co-expressions of ERa and ERp in the spontaneously developed and hormone-
induced mammary tumors in female Noble rats also indicate that there could be 
some degree of interactions between the two ER isoforms. On the other hands, this 
observation also suggests that the development of these mammary tumors may be 
dependent on estrogen to larger extent as compared with the carcinogen-induced 
neoplasms. In the present study, the observed differences in the behaviors and 
hormone receptor status between the carcinogen-induced mammary tumors and the 
spontaneously developed as well as the hormone-induced neoplasms are interpreted 
as a result of the discrepancy in the process of carcinogenesis. As mutations of 
different oncogenes and tumor suppressor genes are involved during the mammary 
gland carcinogenesis in these different animal models, the conversion of the varied 
genetic information into a defined phenotype may lead to a discrepancy in the 
hormone receptor status between the carcinogen-induced mammary tumors and the 
spontaneously developed as well as the hormone-induced neoplasms. 
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4.10 Expressions of PR Proteins in Spontaneously Developed, Hormone 
Induced and Carcinogen Induced Mammary Tumors in Female Noble Rats 
The expression patterns of PR in the mammary glands and breast tumors of 
female Noble rats are similar to that of the ERa. In the normal mammary gland and 
all different classes of mammary tumors, a moderate to strong PR immunoreactivity 
was observed. The co-expression of ERa and PR in the normal and neoplastic 
mammary epithelium is not unique in Noble rats. Previous studies on human breast 
cancer have shown that about 50% of ERa-positive breast tumors are also positive 
for PR (Sharyl & Nancy, 1999; Bamberger et al” 2000). A similar observation is 
also described in the carcinogen-induced mammary tumors in rodent, including both 
DMBA-induced (lino et al, 1990) and NMU-induced (Martin et al.，1996) 
neoplasms. In the NMU-induced breast tumors, it is reported that all the induced 
neoplasm are positive for both ERa and PR regardless the tumor histopathological 
varieties (Martin et al., 1996). On the other hand, co-expression of ERa and PR has 
also been depicted in the normal epithelium in human breast tissues and rodent 
mammary glands (Russo et al, 1999). These extensive co-expressions of ERa and 
PR in both normal and neoplastic breast tissues can be explained by the fact that 
ERa is a key transcription factor for the expression of PR and induction of PR 
expression is one of the main functions of ERa in the breast epithelium (Read et al, 
1988; Shigehira et al, 2000). Therefore, the expression of PR in ERa-positive 
mammary tumors is an expression of ERa functionality (Martin et al., 1996). In the 
present study, there is intense co-expression of ERa and PR in the normal mammary 
glands as well as the spontaneously developed, hormone-induced and carcinogen-
induced mammary tumors in female Noble rats. The expression of PR may be 
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induced by the functionally active ERa as these mammary glands and tumors are 
also positively stained with ERa. 
Western blot analysis revealed that mammary glands and all classes of 
mammary tumors in female Noble rats express PR-A2 isoforms. Elevated 
expressions of PR-B and PR-Al isoforms are also detected in the spontaneously 
developed carcinoma. Due to the inadequacy in the understanding of biological 
functions of PR isoforms, the significance of these observations is still undefined in 
the present stage. On the other hand, there are also expressions of PR-C isoform in 一 
the normal mammary glands, spontaneously developed, carcinogen-induced and 
T+E2-induced mammary tumors. However, in the T+DES induce carcinomas, 
protein expression of PR-C was not detected. It is speculated that the difference in 
the PR-C expression between the T+DES-induced carcinomas and other classes of 
mammary tumors may be due to the distinct estrogenic activity of the synthetic 
estrogen, DES, as compared to the physiological estrogen, E2. In the T+DES-treated 
animals, DES may induce a distinct estrogenic regulation on PR expressions. 
Therefore, absence of PR-C isoform is only observed in the T+DES-induced 
carcinomas, but not in the other classes of mammary neoplasms and the normal 
glands, 
4.11 Expressions of AR Proteins in Spontaneously Developed, Hormone 
Induced and Carcinogen Induced Mammary Tumors in Female Noble Rats 
Positive AR immunoreactivity was detected in the normal mammary glands 
of female Noble rats. The co-expression of AR and ER (ERa & ERp) in the normal 
mammary epithelium could probably explain the high sensitivity of female Noble 
rats to the combined androgen and estrogen treatment for the induction of mammary 
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tumors (Xie et al” 1999). On the other hand, a moderate to strong AR reactivity was 
also detected in the spontaneously developed, hormone-induced and carcinogen-
induced mammary tumors. These consistent expressions of AR immunoreactivity in 
all classes of mammary neoplasms suggest that androgen may play a role in the 
mammary gland carcinogensis. Western blot analysis also shows that the AR-B 
isoform was markedly elevated to different extents in all classes of tumors. In the 
spontaneously developed mammary tumors, an elevated expression of the AR-A 
protein was also detected. Although the biosynthesis and function of the androgen 
receptor isoforms in the mammary gland and tumors are largely unknown in the _ 
current stage, elevated expressions of the AR isoforms in the neoplastic mammary 
tissues suggest the possibility that androgen and its receptor may participate in the 
mammary gland carcinogensis (Catalano et al” 2000). A review on literatures 
suggests that the role of androgen on the development of the breast tumor can be 
multi-discipline. On one hand, androgen can promote the proliferation of breast 
cancer cells directly via the androgen receptor-mediated mechanism or by its 
stimulation on the synthesis of other growth factors (Xie et al, 1999b; 1999c; 2000). 
On the other hand, the action of androgen may also be indirect. Firstly, androgen can 
be converted into estrogen by the enzyme aromatase (Bernstein and Ross, 1993). 
Clinical studies have already shown that estrogen, derived from the systemic 
conversion in peripheral tissues or from the local conversion in the breast tumors, 
participates in the maintenance and growth of the breast tumors in the carriers, 
especially in the postmenopausal females (Chen, 1998). Alternatively, androgen can 
also act indirectly by increasing the circulating amount of free estradiol, via either 
reducing the secretions of hepatic estradiol-bound sex hormone binding globulin 
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(SHBG) by the liver or decreasing the fraction of the SHBG, thereby providing 
substantial amount of estrogen for tumor growth (Lonning et al” 1995). 
The expressions of both AR-A and AR-B isoforms in the spontaneously 
developed mammary tumors provide an interpretation for the continuous growth of 
the spontaneous mammary tumors in the bilateral ovariectomized Noble rats. The 
presence of the steroid hormone receptors (ERa, ERp, PR and AR) and cytokine 
receptor (PRLR) (to be discussed later) in the spontaneously developed mammary 
tumors suggests that the growth and development of the spontaneous neoplasm, to 
large extents, depends on the steroids (estrogen, progesterone and androgen) and 
peptide hormones (prolactin). Although ovariectomy is able to reduce the 
endogenous secretions of estrogen and progesterone, the growth of spontaneously 
mammary tumors is still under the influences of androgen and prolactin. The 
alterations in the hormonal environments following ovariectomy may modify the 
hormone dependency of the spontaneously developed mammary tumors. After the 
ovariectomy, androgen and prolactin, or with other endocrine factors, may be 
responsible for the growth of the spontaneous mammary neoplasms. Therefore, the 
mammary tumors continue to grow even the endogenous secretions of estrogen and 
progesterone is significantly reduced. 
The intense expression of AR in the hormone-induced mammary tumors in 
female Noble rat is consistent with a previous reported (Xie et al” 1999b). In a series 
of studies carried out by Dr YC Wong and his associate in the hormone-induced 
models in female Noble rat, the promoting role of androgen in the mammary gland 
carcinogenesis is speculated (Xie et al, 1999b; 1999c; 2000). It is suggested that 
androgen acts by upregulating the Bax protein expression and thus inducing a high 
apoptotic activities in the normal mammary epithelial cells. This results in a selective 
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pressure favoring the clonal expression of the neoplastic cells. On the other hand, it 
is also speculated that androgen also provokes the selective mechanism via an 
upregulation of TGF-pi expression. TGF-pi has the ability to inhibit the growth of 
normal epithelial cells. When the neoplastic cells become refractory to the biological 
actions of TGF-pl, the presence of TGF-|31 will pose a selective advantage for the 
outgrowth of the transformed clone because it only inhibits the proliferation of the 
normal cells. Thus, the final outcome of androgen's effects would be an increased 
mammary tumor incidence and shorter latency period of mammary tumors. -
A strong AR Immunoreactivity was also detected in the carcinogen-induced 
mammary tumors in female Noble rat. Previous in vitro and in vivo studies also 
reported that AR expresses in the DMBA-induced mammary tumors (Ip et al, 1978; 
Vignon et al, 1979). In contrast to the stimulating role of androgen in the hormone-
induced mammary gland carcinogenesis, it has been shown that androgen and AR 
are involved in the inhibition of growth of the DMBA-induced mammary tumors 
(Gatto etal, 1998). 
So far, the roles of androgen and AR in the mammary gland carcinogenesis 
are still controversial. In the present study, it is speculated the continuous growth of 
the spontaneously developed mammary tumors in the ovariectomized Noble rats and 
the shortened latency period of the hormone-induced mammary tumors are due to 
the stimulatory role of androgen and AR on the carcinogenic process. However, in 
the DMBA-induced models, it is previously report that androgen and AR are 
involved in the regression of the breast neoplasms (Gatto et al, 1998). These 
conflicting observations may suggest the possibility that androgen and AR plays a 
different role in the development of breast cancer between the carcinogen-induced 
models and the spontaneously developed as well as the hormone-induced models. 
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This discrepancy in the biological activities of androgen and AR may be a result of 
the difference in the carcinogenic mechanisms between these models. However, 
more studies are required to confirm this hypothesis. 
4.12 Expressions of PRLR Proteins in Spontaneously Developed, Hormone 
Induced and Carcinogen Induced Mammary Tumors in Female Noble Rats 
A moderate to strong PRLR immunoreactivity was detected in both normal 
mammary glands and breast tumors in the spontaneously developed, hormone-
induced and carcinogen-induced models of female Noble rats. These observations 
are consistent with the clinical studies on human breast cancers. It was previously 
demonstrated by immimocytochemistry that over 93 % of normal human breast 
tissues and over 95 % of the human breast tumor expressed the PRLR (Reynolds et 
a/., 1997). The involvement of prolactin and PRLR are also well studied in the 
murine and rodent mammary cancers. In mice, prolactin is found directly 
contributing to the etiology of both spontaneously developed and carcinogen-
mduced mammary carcinomas (Welsch and Nagasawa, 1977). Prolactin can also 
interact with the ovarian steroids synergistically in the promotion on the growth of 
human breast cancer xenografts in nude mice (Leung and Shiu, 1981). In rats, there 
is a direct association between the serum prolactin level and the susceptibility of the 
animals to the chemical induction of mammary tumors (Boyns et al, 1973). Tumors 
induced in rat by NMU or DMBA are also dependent on prolactin for sustained 
growth (Mershon et al, 1995). In the present study, the presence of PRLR in 
mammary tumors of female Noble rats further suggests that prolactin participates in 
• the mammary gland carcinogensis. 
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On the other hand, in the DMBA-induced mammary tumors, it is observed 
that the immunoreactivity of PRLR is stronger than the reactivity demonstrated by 
the steroid hormone receptors, including ERa, ERp, PR and AR (Table 3.7.). These 
observations further solidify the participation of prolactin in the carcinogen-induced 
model. The strong PRLR reactivity suggests that the growth of the DMBA-induced 
tumors could be largely depend on prolactin. This observation is consistent with the 
previously reported data (Mershon et al, 1995). 
The expression of PRLR in the spontaneously developed mammary tumors in 
female Noble rat also provides a reasonable explanation for the continuous growth of 
the spontaneous neoplasm in the ovariectomized Noble rats. The strong PRLR 
reactivity suggests that the growth of the spontaneous neoplasm may be also 
dependent on prolactin. After the depletion of progesterone and estrogen by 
ovariectomy, prolactin, alone or in combined action with other hormonal factors, 
such as androgen, is responsible for the sustained growth and development of the 
breast tumors. 
In the present study, it is observed that the expression patterns of ERa and 
PR in the mammary tumors of female Noble rats are very similar to that of PRLR. 
Breast tumors in the spontaneously developed, hormone-induced and carcinogen-
induced models of female Noble rats, all exhibit moderate to strong PRLR, ERa and 
PR immunoreactivities. These observations suggest that the expression of PRLR is 
correlated with the expression of ERa and PR. The co-expression of PRLR with 
steroid receptor is also depicted in the human breast tumors (Bonneterre et al. 1982; 
Bonneterre et al, 1986). These observations also raise a possibility that the sex 
steroid hormones, estrogen and progesterone, may interact synergistically with 
prolactin to control the neoplastic growth of the mammary gland. In the current 
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stage, the cellular mechanism for this hormonal synergy is still uncertain. However, 
according to our observation,' the synergy mechanism may involve the cellular co-
expression of steroid and prolactin receptors and their cross-regulations. 
The commercial available antibody used in the immunohistochemistry and 
Western blot analysis under the present study is able to recognize the ligand binding 
site of the rat PRLR. This antibody is also capable of inhibiting the interaction of 
prolactin with PRLR in vitro (Okamura et al, 1989). As the long and short isoforms 
of the PRLR only differ in the length of the cytoplasmic domain (Shirota et al, 
1990)，this PRLR antibody can also recognize both the short and long form of 
PRLR. It has been reported that PRLR is widely expressed in different tissues, 
among which the mammary gland expresses the long form predominantly whereas 
the liver expresses the short form predominantly (Nagano & Kelly, 1994). Due to the 
enzymatic modifications during or after the translation and the difference in tissue 
and species source, immunoreactive PRLR varying in size from -40 kDa to 100 kDa 
are depicted (Guillaumot and Cohen, 1994). In the present study, western blot 
analysis for PRLR has detected expressions of a PRLR protein with a molecular size 
of about 65kDa in the normal and neoplastic mammary samples. This protein is 
regarded as the long isoform PRLR. The physiological roles of the long form PRLR 
in lactating mammary gland are well established. It is reported that long PRLR is 
involved in the stimulation of milk protein synthesis at both transcriptional and 
translational levels (Lesueur et al, 1991; Shirota et al., 1995). The presence of long 
PRLR in the mammary tumors of female Noble rats further suggests that this PRLR 
isoform also participates in the mammary gland carcinogenesis. 
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Chapter 5. Conclusions 
In the present study, it was observed that female Noble rats were susceptible 
to carcinogen and steroid hormone treatments for the induction of mammary tumors. 
On the other hand, spontaneous mammary tumors were also developed in high 
incidence rate in female Noble rats. A comparison of the incidence rate, lengths of 
latency period and histopathology of the mammary tumors developed in these three 
different rat models suggests that hormonal treatment is able to accelerate the 
spontaneously developed carcinogenesis in the mammary glands of female Noble 
rats. On the other hand, it is believed the carcinogen-induced mammary gland 
carcinogensis occurs through a different mechanism as compared with the 
spontaneously developed and hormone-induced mammary gland carcinogenesis. The 
differences of the hormone receptor status between the carcinogen-induced 
- mammary tumors and spontaneously developed as well as hormone-induced tumors 
as revealed by immunohistochemistry and western blotting further support the notion 
that the process of mammary gland carcinogenesis in the carcinogen-induced model 
is different from that of the spontaneously developed and hormone-induced models 
in the female Noble rats. 
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